

Cite this: *Chem. Sci.*, 2023, 14, 409

Metal complexes for catalytic and photocatalytic reactions in living cells and organisms

Hugo Madec,^{†a} Francisca Figueiredo,^{†b} Kevin Cariou,^{*b} Sylvain Roland,^{*a} Matthieu Sollogoub^{†b} [✉]^{*,a} and Gilles Gasser^{†b} [✉]^{*,b}

The development of organometallic catalysis has greatly expanded the synthetic chemist toolbox compared to only exploiting “classical” organic chemistry. Although more widely used in organic solvents, metal-based catalysts have also emerged as efficient tools for developing organic transformations in water, thus paving the way for further development of bio-compatible reactions. However, performing metal-catalysed reactions within living cells or organisms induces additional constraints to the design of reactions and catalysts. In particular, metal complexes must exhibit good efficiency in complex aqueous media at low concentrations, good cell specificity, good cellular uptake and low toxicity. In this review, we focus on the presentation of discrete metal complexes that catalyse or photocatalyse reactions within living cells or living organisms. We describe the different reaction designs that have proved to be successful under these conditions, which involve very few metals (Ir, Pd, Ru, Pt, Cu, Au, and Fe) and range from *in cellulo* deprotection/decaging/activation of fluorophores, drugs, proteins and DNA to *in cellulo* synthesis of active molecules, and protein and organelle labelling. We also present developments in bio-compatible photo-activatable catalysts, which represent a very recent emerging area of research and some prospects in the field.

Received 12th October 2022
Accepted 1st December 2022

DOI: 10.1039/d2sc05672k

rsc.li/chemical-science

1. Introduction

While Nature has long used metal catalysts, such as metallo-enzymes, to perform transformations with exquisite selectivity and efficiency, the heyday of metal catalysis is still relatively

recent. The last few decades have seen transition metal complexes rise from lab curiosities to indispensable tools for synthesis. Quite logically, the implementation of metal-based catalysis in biorelevant environments became a bonafide field of research.^{1–3} One of the key aims is to develop metal complexes

^aSorbonne Université, CNRS, Institut Parisien de Chimie Moléculaire, Paris, France. E-mail: sylvain.roland@sorbonne-universite.fr; Web: <http://www.ipcm.fr/>-Glycochimie-Organique

^bChimie ParisTech, PSL Université, CNRS, Institute of Chemistry for Life and Health Sciences, Paris 75005, France. E-mail: kevin.cariou@chimieparistech.psl.eu; gilles.gasser@chimieparistech.psl.eu; Web: <http://www.gassergroup.com>

[†] These authors have contributed equally to this work and should be considered co-first authors.



Hugo Madec completed his MSc in Molecular chemistry at Sorbonne University in 2021. He is currently a PhD candidate under the supervision of Sylvain Roland and Matthieu Sollogoub at Sorbonne University. His research is focused on the development of biocompatible encapsulated copper photocatalysts.



Francisca Figueiredo graduated from the Université de Paris and completed her MSc in Chemistry for Life Sciences at PSL University in 2021. She is currently doing her PhD under the supervision of Gilles Gasser and Kevin Cariou at Chimie ParisTech, on copper complexes to perform intracellular photocatalysis for anticancer purposes.



capable of selective and safe catalysis *in cellulo* and *in vivo* to modulate cellular functions and bring about new-to-nature transformations into living organisms.^{4–6} Apart from its fundamental aspect, this approach opens new perspectives for the development of more efficient and selective therapeutic treatments and *in vivo* imaging processes.

Metal-based catalysis in complex biological systems faces several challenges. Once metal complexes enter a living organism, they are exposed to natural chelators and high concentrations of nucleophiles such as thiols and amines, in particular glutathione.⁷ These species can deactivate or capture the metal compounds/metal ions and accelerate their elimination from the body. Another potential problem is that some metals used in catalysis may have unwanted adverse toxicity towards cells, although it is important to remember that very high doses of some metal complexes are used on an every-day basis in medicine (e.g., Ga-based MRI agents).⁸ Therefore, it is generally important to develop catalysts that are active at low concentrations to minimise the risk of unwanted toxicity and

side effects. Finally, *in cellulo* monitoring of metal-based catalysis may encounter some barriers due to the complex biological environment of cells and the lack of direct quantitative analytical methods.⁹ For instance, the exact proportion of the catalyst which enters the cells or the amount that is trapped inside membranes remains difficult to precisely quantify. As a consequence, the evaluation of turnover numbers and catalytic activity, which are classical tools to compare the efficiency of metal complexes in catalysis, is also difficult.

The field has evolved in the last few years towards a broader range of transformations with an increasing number of metals (including non-precious metals) and towards photocatalysis, which is a new challenge for cellular applications. Various strategies have been developed including *in cellulo* prodrug activation, profluorophore and protein activation or small molecule (NO) release through metal-(photo)catalysed decaging, *in cellulo* synthesis of active molecules, labelling through metal-catalysed conjugation reactions or exploiting intracellular reagents (NAD(P)H and GSH) to disturb cell processes. Some of



Kevin Cariou received his PhD in 2006 from Sorbonne Université under the supervision of Max Malacria and Louis Fensterbank. From 2007 to 2009, he worked as a postdoctoral researcher in the group of Alison Frontier at the University of Rochester (NY, USA). He was appointed as a CNRS Researcher in 2009 at the Institut de Chimie des Substances Naturelles in the team led by Robert Dodd. He obtained his

HDR in 2015 and moved to Chimie ParisTech in 2020 and was appointed the Director of Research in 2021. His interests lie in the development of synthetic methods to access biologically active molecules.



Matthieu Sollogoub is Professor of Molecular Chemistry at Sorbonne University, where he conducts his research on various aspects of organic, biological and supramolecular chemistry. He focuses mainly on cyclodextrin functionalization for catalysis, supramolecular assembly and molecular motors. He obtained his PhD at the Ecole Normale Supérieure (ENS) in Paris in 1999 with Prof. P. Sinaÿ. He carried out post-

doctoral research at the University of Southampton with Prof. T. Brown and joined the faculty of ENS and Sorbonne in 2001. In 2011, he received the Carbohydrate Research Award for Creativity in Glycoscience, and in 2020 he became a Chemistry Europe Fellow.



Sylvain Roland is an Associate Professor at Sorbonne Université in Paris. He holds a MSc in Organic and Bioorganic Chemistry (1991) and received his PhD in 1995 (Organic Chemistry) from Pierre and Marie Curie University under the supervision of Prof. J.-P. Genêt at the Ecole Nationale Supérieure de Chimie de Paris. In 1995–1996, he joined Prof. W. B. Motherwell's group at University

College London as a postdoctoral fellow. His recent research interests are in the area of metal–NHC complexes and encapsulated metals with applications in homogeneous catalysis and application of cyclodextrin–NHC–metal complexes in bioorganometallic chemistry and *in vivo* photocatalysis.



Gilles Gasser started his independent scientific career at the University of Zurich (Switzerland) in 2010 before moving to Chimie ParisTech, PSL University (Paris, France) in 2016 to take a PSL Chair of Excellence. Gilles was the recipient of several fellowships and awards including the Alfred Werner Award from the Swiss Chemical Society, an ERC Consolidator Grant, the European BioInorganic Chemistry (Euro-

BIC) medal and the Pierre Fabre Award for therapeutic innovation from the French Société de Chimie Thérapeutique. Gilles' research interests lay in the use of metal complexes in different areas of medicinal and biological chemistry.



these strategies allow for specific targeting of cells and cell components and thus may favour the development of future treatments with restricted side effects. Photocatalysis is a particularly relevant tool in this area,¹⁰ enabling precise light-activation of a catalyst in a spatio-temporal controlled manner. Overall, the *in cellulo* use of metal-based catalysts has already demonstrated its pertinence and potential for developing new tools for therapeutic and biomedical applications,¹¹ but many catalytic reactions and metals remain to be explored.

Since it is an emergent field, several excellent reviews, which are dedicated, for example, to catalysis in biologically relevant conditions using nanoparticles^{3,12} or discrete organometallic complexes^{13,14} have been (recently) published. Also, some reviews focus on the applications of metal-based catalysts as therapeutics in medicine.^{15–18} While these reviews are organised by metal ions,^{11,19–21} applications or the type of reaction^{22–25} in biological habitats but not within living organisms, herein we present the recent breakthroughs in the biological applications of metal-based catalysts and photocatalysts within living cells and organisms. Of note, we only focus on catalytic transformations performed inside cells, bacteria and vertebrates (mainly mice or zebrafish). Finally, this review describes homogeneous catalytic systems using discrete metal complexes.

2. Ruthenium

Ruthenium catalysts have been widely used in homogeneous catalysis for a wide range of transformations ranging from CH activation²⁶ to olefin metathesis.²⁷ Furthermore, Ru complexes are classically used as photosensitizers in photoredox processes.^{28–30} Concerning *in vivo* applications, several Ru-based compounds have been tested for their anticancer properties,³¹ some of them having reached the clinical study phase (KP1339,³² NAMI-A,³³ and TLD1443 (ref. 34 and 35)). It is therefore logical that Ru was one of the first metals to be used as a catalyst and photocatalyst *in cellulo*.

2.1 Catalysis

As early as 2006, Meggers and co-workers showed that Ru complexes could induce uncaging of Alloc-protected substrates in living cells. This was initially reported in mammalian cells with a ruthenium(II) complex [Cp*Ru(cod)Cl] (**1**) (Cp* =

pentamethylcyclopentadienyl, cod = 1,5-cyclooctadiene) (Fig. 1).³⁶ In a preliminary study, it was shown that the Ru^{II} complex **1** was tolerant to air and water but that thiols (thiophenol) were essential for catalytic activity. The uncaging reaction was evaluated inside mammalian *HeLa* cells after incubation with 100 μM of a caged rhodamine 110 dye **2**, which is a profluorophore with low fluorescence. After incubation with the Ru catalyst (**1**) (20 μM) and thiophenol, a 10-fold increase of fluorescence was observed inside cells indicating intracellular fluorophore **3** production through Alloc deprotection. By comparison, a 3.5-fold increase was measured in the control experiments without the catalyst. Control experiments without the supplementation of thiophenol also showed a limited fluorescence increase (3.5-fold) demonstrating the importance of thiols as nucleophiles to favour the reaction. Cell-staining experiments suggested that the fluorescence occurs within cells rather than on the membrane, thus implying that compound **1** can diffuse through membranes to induce intracellular catalysis. Furthermore, cytotoxicity experiments with the catalyst alone displayed no decrease in cell viability.

In 2014, the same group developed an organometallic ruthenium(IV) complex (**4**) catalysing the uncaging of Alloc-protected amines with high turnover numbers (TONs), reaching 270 cycles in aqueous medium in the presence of thiols (Fig. 2).³⁷ Inside living *HeLa* mammalian cells preincubated with Alloc-caged rhodamine 110 **5**, an average of a 90-fold increase of intracellular fluorescence was observed after 10 minutes of treatment with the cationic complex **4**, a clear improvement compared to the initial study with the Ru^{II} complex **1** (Fig. 1). The ability of the Ru^{IV} complex **4** to diffuse through the cell membrane was demonstrated. The authors also investigated the influence of cytoplasmic thiols on the activity of the catalyst. They discovered that thiols induced the activation of the Ru^{IV}(allyl) complex, leading to improved efficiency in the decaging reaction, in contrast to previous Ru catalysts, which were deactivated by thiols. Finally, the uncaging of the anti-cancer drug doxorubicin **6** inside *HeLa* cells was developed (Fig. 2B) by using an *N*-Alloc protected doxorubicin prodrug **5**, exhibiting significantly reduced overall affinity for DNA compared to the drug itself. Cells incubated with the prodrug (50 μM or 100 μM) and the Ru^{IV} catalyst **4** (20 μM) showed a dramatic decrease in cell viability (reduced to 7% and 2%, respectively), whereas cells treated with the prodrug or complex **4** only were not affected. This demonstrated the efficiency of the




Fig. 1 Ruthenium(II)-catalysed Alloc deprotection of the caged fluorophore to rhodamine 110 in *HeLa* cells in the presence of thiols.³⁶






Fig. 2 (A) Structure of the cationic ruthenium(IV) precatalyst **4**; (B) Ru-induced uncaging of the anticancer drug doxorubicin inside *HeLa* cells.³⁷

Ru precatalyst **4** to induce uncaging of doxorubicin **6** inside cells, leading to apoptosis.

In 2014, Mascareñas and coworkers reported a Ru-based decaging strategy for the *in cellulo* control of the selective targeting of double stranded DNA by small molecules, such as ethidium bromide or DAPI (4',6-diamidino-2-phenylindole).³⁸ External control of DNA binding to these molecules is interesting for regulating DNA transcription and thus gene expression. Adding Alloc protecting groups to DAPI and ethidium bromide was first shown to reduce the affinity to DNA and thus to deactivate their function. These two DNA binding agents have intrinsic fluorescence, allowing for the monitoring of their cellular distribution and activity. The uncaging reaction was tested inside chicken embryo fibroblast (CEF) cells with 2.5 μM of caged DAPI and 2.5 μM of the ruthenium(II) catalyst [RuCp*(COD)Cl] (**1**). Before incubation with **1**, fluorescence microscopy showed whole cell staining as DAPI did not interact with DNA and was therefore spread throughout the cell. After 20 minutes of treatment, the typical blue DAPI staining shifted from the cytoplasm to the cell nucleus, strongly supporting that the Ru^{II} catalyst **1** did induce intracellular uncaging, leading to DAPI release and DNA binding. As previously observed, the presence of thiol (PhSH, 100 μM) is required for efficient Alloc deprotection. Furthermore, the di-Alloc DAPI derivative was found to induce better intracellular staining than DAPI, suggesting a better internalisation inside cells. Finally, the effect of uncaging of DNA binding molecule **7** into **8** on cancer cell growth was studied. Cisplatin-resistant A2780 cells (human ovarian carcinoma) were incubated with both protected (**7**) and unprotected (**8**) phenyl azapentamidine derivatives (Fig. 3). The inhibitory effect of the caged derivative **7** ($\text{IC}_{50} = 5.0 \mu\text{M}$) decreased by 10-fold compared to the uncaged molecule **8** ($\text{IC}_{50} = 0.4 \mu\text{M}$). Overall, this study demonstrated the potential of *in cellulo* Ru-based uncaging reactions for controlling the activation of small DNA-binding molecules in biological media.

The same authors reported in 2016 a Ru^{IV}(allyl) complex **9a** that accumulates inside the mitochondria of living mammalian cells to catalyse the targeted uncaging of allyl/Alloc protected substrates in this organelle (Fig. 4).³⁹ An active Ru^{II} species is likely to be generated *in cellulo* through the reduction of the Ru^{IV}(allyl) species by intracellular thiols. The specific localisation of the catalyst and its retention in mitochondria were guaranteed by using a triphenylphosphonium (TPP) delivery vector linked to the ruthenium complex *via* a hydrophobic alkyl chain. TPP cations have the property to diffuse through the mitochondrial inner membrane. Cellular tests were performed in *HeLa* cells, for which catalyst **9a** did not show any toxicity even at concentrations >100 μM . Incubation with Alloc-protected rhodamine **2** together with **9a** showed an intracellular increase of fluorescence, mainly concentrated inside mitochondria. To monitor the Ru-catalysed deprotection reaction by fluorescence, an analogue of **9a** possessing a pyrene unit (**9b**) was developed (Fig. 4A). To test the catalytical capacity of this new complex, cells were treated with 100 μM of a caged rhodamine 110 dye **2** and 50 μM of catalyst **9b**. The pattern of the green fluorescence of the free rhodamine **3** was found to match the blue fluorescence of **9b** and the red staining identifying the mitochondria. These results, demonstrating that catalysis did take place in mitochondria, were reproduced in A549 cancer cells. This work shows that it is possible to have an abiotic catalyst, not initially present in living organisms, acting in a precise subcellular compartment.

Ward and co-workers reported in 2018 a cell-penetrating ruthenium-based Artificial Metalloenzyme (ArM) **10** catalysing Alloc deprotection in epithelial human cells.⁴⁰ This ArM **10** was built from the biotin *N*-binding protein streptavidin, combining a biotin *N*-linked ruthenium(II) complex **11** that catalyses the uncaging reaction of the Alloc-protected substrate **14** and a biotinylated cell-penetrating moiety having a fluorescent probe **12** (Fig. 5A). Cellular tests were performed in HEK-293T




Fig. 3 Ru-catalysed decaging of double stranded DNA binding agents by [RuCp*(COD)Cl] (**1**) inside A2780 cancer cells.³⁸







Fig. 4 (A) Structure of mitochondria targeting Ru^{IV} complexes **9a** and **9b**; (B) catalysis of the uncaging of fluorophore rhodamine 110 inside *HeLa* and *A549* cells, preferentially occurring inside mitochondria.³⁹

A: ArM construction



B: Reaction




Fig. 5 (A) Assembly of a cell-penetrating Ru-based artificial metalloenzyme (ArM). The ruthenium catalyst and the fluorescent probe/cell penetrating peptide are both attached to biotin units interacting with streptavidin to create the artificial metalloprotein; (B) the ArM catalyses the Alloc deprotection of compound **14**, generating the hormone **15**. The *HEK-293T* cells have been modified to become fluorescent once **15** is liberated.⁴⁰



cells, which were successively incubated with ArM **10** and the Alloc-protected prosubstrate **13**. When incorporated into cells, **13** is hydrolysed by endogenous esterases to give the alloc-protected substrate **14**. The uncaging of **14** by ArM **10** releases the hormone **15** that activates a metabolic cascade (Fig. 5B). The cells were previously transfected with two genes that change the outcome of the metabolic cascade when the hormone is deprotected, leading to cell fluorescence and allowing for reaction monitoring. The increase in fluorescence in cells confirmed that ArM **10** catalysed Alloc deprotection to release the hormone. This was not observed in cells treated with the ruthenium catalyst only. Furthermore, no cytotoxicity induced by the catalyst was detected at concentrations below 500 nM. The optimisation of the ArM was performed by site-directed mutagenesis at two positions close to the catalytic centre, and the best TONs were obtained for the mutation of a serine in position 112 into an alanine.

Mao and co-workers reported in 2022 a ruthenium-based catalyst **16**, which is attached to a HER2 antibody that targets the receptor on the membrane of HER2-positive cancer cells.⁴¹ Complex **16** catalyses the activation of a gemcitabine prodrug **17** via Alloc deprotection to form the free primary amine **18**, which

enters the cell to cleave DNA. Cell death is also induced by blocking of the HER2 signalling pathway by the ruthenium(IV)-antibody complex (Fig. 6). Cell tests performed with *SKBR-3* HER2-positive cancer cells confirmed, after incubation with the prodrug **17** and Ru^{IV} catalyst **16**, that the reaction was catalysed by the ruthenium complex at the cell surface. The specificity of this treatment was confirmed by comparing cell death in a co-culture of *SKBR-3* cells and *MCF-10A* non-tumorigenic cells incubated with both the Ru^{IV} complex **16** and the alloc-protected prodrug **17**. 75% cell death was observed for the HER2-positive cells, whereas HER2-negative cells showed only 15% cell death. Next, 3D spheroids of *SKBR-3* cells were developed and incubated with 40 μM of prodrug **17** and 2 μM of the Ru^{IV} complex **16**. This treatment led to a decrease of cell viability in spheroids, reaching 32%. Finally, *in vivo* tests were performed in zebrafish larvae grafted with *SKBR-3* cells, in which 2 μM of the Ru^{IV} complex **16** and 8 μM of the alloc-protected prodrug **17** were injected. Fluorescence images revealed a decrease in *SKBR-3* cell fluorescence in the zebrafish larvae by ca. 78%, indicating significant cell death. To the best of our knowledge, this study described the first ruthenium-antibody catalyst capable of performing HER2-targeted chemotherapy.

Beside Alloc deprotection reactions, other types of Ru-catalysed reactions have been developed in eukaryotic and prokaryotic cells. Sadler and co-workers described in 2015 a system based on Noyori-type Ru^{II} arene complexes and formate ions that disrupt the NAD⁺/NADH balance in cells by reducing NAD⁺ to NADH, inducing selective cancer cell death (Fig. 7).²³ The authors showed that complex **19** bearing a sulfonyl ethyldiamine ligand catalysed transfer hydrogenation inside living cells in the presence of non-toxic concentrations of formate acting as a hydride donor. The formation of Ru-H hydride species by mixing the Ru^{II} complex **19** and formate ions was evidenced by ¹H NMR and mass spectroscopy. In *A2780* human ovarian cancer cells, the catalyst **19** alone exhibited an antiproliferative activity comparable to that of cisplatin (IC₅₀ 2.2 and 1.2 μM, respectively). However, in the presence of formate ions, the antiproliferative activity was found to be greatly increased (up to 50-fold), supporting a direct contribution of formate in the intracellular catalytic cycle of transfer hydrogenation. The comparison of antiproliferative activity towards normal cells (*MRC5*) and *A2780* cancer cells also showed that formate increased the selectivity factor from 3.6 to 5. Complex **19** is mainly distributed in the cytosol (51%), as shown by ICP-MS experiments. Experiments carried out on *A2780* human ovarian cancer cells revealed that the mechanism of cell death *via* reductive stress caused by the disruption of the NAD⁺/NADH balance was different from other anticancer modes of action. According to the authors, this means that this new approach could be efficient against cisplatin-resistant cancer cell lines.

Mascareñas and co-workers described in 2019 Ru^{IV} complexes catalysing the intracellular isomerisation of allylic alcohols into saturated carbonyl derivatives by intramolecular hydride transfer.⁴² To understand whether the reaction could be carried out inside cells, the authors designed a ruthenium complex **20** and a substrate **21**, whose isomeric form **22** is




Fig. 6 Schematic illustration of HER2-targeted chemotherapy using a gemcitabine-based prodrug and the Ru^{IV} complex **16** as the catalyst.⁴¹ The prodrug is activated by the catalyst near the membrane and is taken up by the cell as an active anticancer drug. The reaction was performed *in vivo* inside zebrafish larvae grafted with *SKBR-3* cells.






Fig. 7 Induction of reductive stress in cancer cells by the Ru^{II} arene complex **19** in the presence of formate ions, leading to selective cancer cell death.²³

fluorescent (Fig. 8A and B). The reactions were studied in human A549 and *HeLa* cells as well as animal *Vero* cell lines (Fig. 8C). The treatment of cells with only 10 μM of the Ru^{IV} complex **20** and 100 μM of the non-fluorescent substrate **21** generated significant fluorescence, building up in the cytosol. A TON of over 22 was obtained after 6 h. In this time span, none of the compounds reduced cell viability. Looking for biological applications for this approach, the authors considered to generate *in situ* glutathione depleting agents such as ketone **24** by isomerisation. Inside cells, the incorporation of 100 μM of allylic alcohol **23** and 50 μM of the Ru catalyst **20** led to the intracellular generation of the GSH depleting agent **24**. After 6 h, the authors showed that the formation of **24** was associated with a consumption of over 40% of the intracellular glutathione. They concluded that metal catalysis could be used to generate bioactive molecules inside cells by other strategies not involving uncaging reactions.

In 2020, Mascareñas and co-workers reported the transposition of intramolecular and intermolecular [2 + 2 + 2] cycloaddition reactions inside living mammalian cells using the ruthenium complexes **1**, **25** and **26** (Fig. 9).⁴³ Both the neutral Ru^{II} complex **1** and cationic Ru^{IV} complexes **25** and **26** were

found to be active inside *HeLa* cells and biocompatible, as no change in the cell morphology was observed after the experiments. The presence of the Ru catalyst inside cells was demonstrated by ICP-MS after the incubation of *HeLa* cells with 50 μM of the neutral Ru^{II} complex **1**. The production of a fluorescent probe **28** from substrate **27** by an intramolecular [2 + 2 + 2] cycloaddition reaction was used for the tracking of the reaction inside cells. The incubation of the cells with the Ru complexes **1** or **26** (50 μM) followed by triene **28** (100 μM) showed that cells incubated with the cationic Ru^{IV} complex **26** exhibited three times more fluorescence than those incubated with the neutral Ru^{II} complex **1**. These results were explained by the good cellular uptake and low toxicity at 50 μM of the Ru^{IV} complex **25** that was previously observed by the authors.³⁹ The transfer of the [2 + 2 + 2] cycloaddition reaction inside cells made possible the *in cellulo* synthesis of molecules, which could not have been internalised without the permeabilisation of the cell membrane. This strategy was applied to the intracellular production of anthraquinones, which are secondary metabolites that cannot be generated by mammalian cells. For instance, the anthraquinone **31**, which presents aggregation-induced emission properties, was synthesised inside *HeLa*




Fig. 8 (A) Ruthenium(IV) complex **20** inducing intracellular isomerisation of allylic alcohols. (B) and (C) Generation of functional unsaturated ketones inside A549, *HeLa* and *Vero* cells.⁴²






Fig. 9 (A) Ru complexes **1** and **25–26** used for intracellular [2 + 2 + 2] cycloaddition reactions; (B) intramolecular and (C) intermolecular cycloaddition reactions promoted by ruthenium complexes inside HeLa cells for the generation of a fluorescent probe (**28**) or an anthraquinone (**31**), respectively.⁴³

cells by using 50 μM of the Ru^{IV} complex **25**, 50 μM of the precursor **29** and 150 μM of **30** through an intermolecular cycloaddition reaction. The formation and the localisation of the anthraquinone **31** were determined by fluorescence microscopy. Finally, the authors showed that the spatial localisation of the as-formed fluorescent molecule **31** could be controlled by using different catalysts. With the ruthenium complex **25**, the product displayed a cytosolic distribution, whereas it was mainly localised inside mitochondria by using the ruthenium complex **26**, a complex known to preferentially accumulate inside mitochondria.

In 2021, Weng and co-workers developed aqueous-stable organo-ruthenium(II) complexes able to perform intracellular reduction of O_2 to H_2O_2 to induce targeted bacteria death through the subsequent generation of ROS such as hydroxyl radicals (HO^\cdot) (Fig. 10).⁴⁴ The initial strategy proposed by the authors depends on the exploitation of endogenous formate as a hydride source to generate Ru–H species for transfer hydrogenation to reduce O_2 . A library of 480 ruthenium complexes was screened to test their ability to generate H_2O_2 in the

presence of air/ HCOONa on a model reaction in aqueous medium. Ten lead complexes were then selected for evaluating their antimicrobial activity on six bacterial strains, including formate abundant strains *S. aureus* (Gram⁺) and *E. coli* (Gram[−]) and formate deficient strains *Mycobacterium smegmatis* (Gram⁺), *B. subtilis* (Gram⁺) and *P. aeruginosa* (Gram[−]). A comparison with normal mammalian cells (*HEK293*) was also performed. Cell viability assays showed that the ruthenium complex **32** presented the best antimicrobial activity, especially against Gram positive bacterial cells. This suggests that **32** boosts ROS production in Gram⁺ compared to Gram[−] bacteria and normal mammalian cells. The fact that **32** is active against both formate abundant and formate deficient Gram⁺ bacteria suggested two different modes of action. The authors showed that the catalyst **32** used two different pathways to reduce O_2 to H_2O_2 inside bacteria involving either hydrogen transfer through a Ru–H intermediate **33** (formate abundant strain) or single electron transfer (SET) *via* the formation of O_2^\cdot radicals (formate deficient strains) (Fig. 27). Finally, the lead organoruthenium complex **32** was shown to be efficient against methicillin-




Fig. 10 ROS generation by a ruthenium(II) complex inside bacterial cells: (A) hydride transfer mechanism in formate abundant Gram⁺ strains and (B) SET mechanism in formate deficient strains.⁴⁴



resistant *S. aureus* (MRSA), paving the way for the development of alternative antimicrobial agents to treat antimicrobial resistance.

The main reaction performed *in cellulo* by Ru complexes was initially limited to the decaging of an Alloc protecting group. In the initial reports, this was only achieved by adding exogenous thiols in addition to the catalyst and substrate. This was later improved by the development of systems that only required endogenous thiols for the decaging to occur. More recent reports have significantly expanded the scope of transformations that could be enabled by ruthenium complexes *in cellulo*, adding isomerization or cycloadditions, for example. On a more critical note, intermolecular reactions between two distinct exogenous substrates, such as the [2 + 2] cycloaddition, despite their conceptual interest, might be very challenging to be transposed in the clinic, due to the use of several independent molecules together.

2.2 Photocatalysis

As stated above, Ru complexes are well-known for their photochemical properties, including in a biological environment,⁴⁵ paving the way to their application as a photocatalyst *in cellulo*. Following their initial work with [Cp*Ru(cod)Cl] (**1**) for intracellular Alloc deprotection under “classical” thermal conditions, Meggers and colleagues reported in 2012 a ruthenium(II) aryl complex **34** able to induce Alloc cleavage under light activation inside *HeLa* cells.⁴⁶ Upon irradiation at $\lambda \geq 330$ nm, the Ru^{II} complex **34** (Fig. 11) forms a [Cp*Ru(solvent)₃]⁺ complex, which is catalytically active, by releasing the pyrene. The presence of thiols as nucleophiles is mandatory to perform the cleavage reaction. The catalyst **34** is more active in the presence of thiophenol than aliphatic thiols. Inside *HeLa* cells, **34** can perform the Alloc cleavage reaction to generate fluorescent rhodamine **3** from Alloc-protected rhodamine **2** (Fig. 11). *HeLa* cells were incubated with the caged rhodamine **2**, washed to remove the non-internalised, protected rhodamine, and submitted to the action of Ru^{II} complex **34** with or without external thiols. After irradiation of the cells for 10 min at $\lambda \geq 330$ nm, the appearance of fluorescence due to rhodamine **3** was observed. Cells incubated with the catalyst **34**, **2** and thiophenol were found to exhibit a fluorescence intensity 70-fold higher than those without thiophenol. Without thiophenol, only

a small increase of fluorescence was observed, thus demonstrating the need for external additional nucleophilic thiol.

Wingsinger and co-workers described in 2012 an abiotic photoreduction of azide-based immolative ligands by a [Ru^{II}(bipy)₃]-type complex bearing a modified phenanthroline (Fig. 12A). The reduction leads to the intracellular uncaging of a rhodamine fluorophore **35** after visible light irradiation.⁴⁷ The photoreduction of the azide to an aniline, according to the mechanism described in Fig. 12A,⁴⁸ entails a decomposition of the immolative linker. The strategy uses one set of protein ligands that bind to an oligomeric receptor. Each protein ligand has been modified by conjugation with a different reactive partner: a rhodamine-based substrate or the Ru^{II} catalyst. The ligands have high affinity for the oligomeric receptor, bringing the two reactive partners into proximity upon binding and inducing an increase of the reaction rate (Fig. 12B). This was achieved with three sets of ligands having affinity for three oligomeric receptors: biotin, desthiobiotin and raloxifene. The system was shown to release rhodamine upon visible light irradiation and in the presence of sodium ascorbate, which makes it suitable for *in cellulo* imaging. The authors studied the reaction inside *PA01* bacteria, having an acetyl CoA carboxylase (ACC) that uses biotin as a cofactor as the oligomeric receptor. When bacteria were irradiated with a 455 nm LED lamp for 30 min, an 8-fold increase in fluorescence was observed, thus demonstrating the fluorophore release. Finally, studies were performed on human *HER2*-driven oncogenic cell lines where ACC is known to be upregulated. It is also known that ACC is more abundant in *BT-474* cells than *MCF-7* cells. This was an opportunity to uncover whether it was possible to determine the cell type depending on the fluorescence intensity. The authors showed that, after irradiation at 455 nm, there was a higher fluorescence intensity for *BT-474* cells than for *MCF-7* cells. As a conclusion, it was suggested that this strategy could be more widely applied to uncage active biomolecules and pharmaceutical compounds in a specific target. For instance, it would be possible to target cells that overexpress certain oligomeric receptors.

In 2013, Wingsinger and coworkers further showed that the photocatalysed reduction of azide-triggered immolative linkers with [Ru(bpy)₃]²⁺ complexes could be applied in cells to detect and image miRNAs.⁴⁹ miRNAs are responsible for the regulation




Fig. 11 Alloc cleavage by photo-activatable ruthenium(II) precatalyst **34** inside *HeLa* cells allowing spatial and temporal control of the reaction.⁴⁶






Fig. 12 (A) Mechanism of the photoreduction of the azide. (B) $[\text{Ru}^{\text{II}}(\text{bipy})_3]$ -type complexes and azide/rhodamine substrates linked to protein ligands for an intracellular protein templated reaction induced by visible light irradiation. Photoreduction of the azide to the aniline leads to immolative linker decomposition and uncaging of rhodamine.⁴⁷

of almost 30% of human genes, and the alteration of their activity is the origin of the development of some cancers, and hence the interest in their imaging and location. This study

focused on miRNAs miR-21 and miR-31 as they are overexpressed in certain types of cancers. The imaging probe consisted of two strands of peptide nucleic acid (PNA) that are




Fig. 13 Nucleic acid templated reaction catalysed by $[\text{Ru}^{\text{II}}(\text{bipy})_3]$ -type complexes under visible light irradiation for imaging of miRNAs in BT474 and HeLa cancer cells.⁴⁹



complementary to two different portions of the targeted miRNA. One PNA bears a lysine residue and the luminescent Ru^{II} complex on its C-terminus. The N-terminus side of the other PNA was conjugated to a molecule containing an azide and a caged rhodamine. The hybridisation of both PNAs and the targeted miRNA would place the Ru complex and the caged fluorophore in proximity and therefore accelerate the reaction of uncaging by the Ru (Fig. 13). For both miRNAs, the authors also made equivalent mismatched probes, where the PNA strand does not correspond to the miRNA targeted strand, as a control. This approach was tested inside *BT474* cancer cells that overexpress miR-21 and *HeLa* cells that overexpress miR-31. In both cases, an increase in fluorescence inside the cells was observed after visible light irradiation, thereby demonstrating that the nucleic acid templated reaction takes place in cells leading to the release of the active fluorophore. Tests performed with the mismatched probe or inside cells with no expression of the target miRNAs revealed no fluorescence, indicating that the PNA strands did not bind to the miRNAs in the control experiments and therefore did not bring the reagents into proximity. The authors believe that this technique could be expanded to the release of masked bioactive molecules.

In 2015, Wissinger and co-workers extended this strategy by using the Ru photocatalyst **36**, to generate a quinazoline precipitating dye **38** that can be imaged in cells (*HEK293T*, *MCF-7* and human bone cancer cells) upon two-photon excitation (730 nm) (Fig. 14).⁵⁰ In this study, complex **36** was linked through phenanthroline to a ligand for specific targeting of proteins either in the intracellular membrane, in the cytosol or in the nucleus. After incubation with cells, the ruthenium-tagged proteins could be localised in their specific cell compartment through luminescence imaging. Thanks to specific protein targeting by the catalyst, the photo-induced (at 450 nm) azide reduction reaction can occur in several chosen subcellular locations. When R is a ligand targeting oestrogen receptor inside *MCF-7* cells, the receptor induces nuclear translocation of the Ru photocatalyst **36**, which once located inside the nucleus of the cells can still perform the photo-induced azide reduction of **37** to the quinazoline precipitating

dye **38** inducing luminescence in the nucleus. Other subcellular locations such as mitochondria can be targeted by using *O*⁶-benzylguanine as the ligand.

In 2013, Nakamura and co-workers developed a new strategy to selectively modify a protein based on local Single Electron Transfer (SET) catalysis induced by the [Ru^{II}(bpy)₃]²⁺ complex **39** (bpy = bipyridine) after visible light irradiation inside mouse erythrocytes.⁵¹ The strategy lies on the linkage of the Ru photocatalyst to a ligand of the protein of interest. After visible-light irradiation, the activated Ru^{II*} performs a SET reaction onto a tyrosine residue of the protein to form the tyrosyl radical and is oxidised to Ru^{III} (Fig. 15). The resulting tyrosyl radical can then react with a fluorescent tyrosyl radical trapping (TRT) agent **40** to label the protein. By using the Ru^{II} complex **39** conjugated with benzene sulfonamide (a ligand of carbonic anhydrase CA) in mouse erythrocytes, the labelling reaction of CA was possible, without modification of other proteins. These results demonstrated that this visible light-induced SET reaction was suitable for bioorthogonal intracellular protein modifications. In order to overcome the limitations of the fluorescence labelling, biotin-conjugated TRT could also be used to enable streptavidin-based detection methods.

In 2015, the same authors reported a similar strategy for inactivating intracellular proteins through a visible light stimulus, using Ru^{II} complexes conjugated with ligands for selective protein targeting.⁵² Upon irradiation but in the absence of tyrosyl radical trapping (TRT) agents, [Ru^{II}(bpy)₃]²⁺ type complexes such as **41** were shown to generate singlet oxygen ¹O₂ leading to the oxidation of histidine, tryptophan and methionine residues in the vicinity of the protein ligand site, leading to the subsequent and selective inactivation (*i.e.* knock-down) of the protein (Fig. 16). The formation of ¹O₂ was detected by using a singlet oxygen green sensor (SOSG). This knockdown reaction was applied inside *A431* cells with the Ru^{II} complex **41**, which was conjugated to gefitinib (in red, Fig. 16), a ligand for the epidermal growth factor receptor (EGFR) (overexpressed in *A431* cell membranes). The incubation of *A431* cells with the Ru-gefitinib compound **41** followed by visible light irradiation was shown, by immunoblotting analysis, to induce a decrease of




Fig. 14 Azide reduction of a pro-fluorescent probe inside different cell lines by the ruthenium(II) complex **36**, which is conjugated with a protein ligand R, allowing specific localisation of the reaction in targeted parts of the cell by two-photon excitation at 730 nm.⁵⁰






Fig. 15 Intracellular visible light-induced targeted protein modification by Single Electron Transfer (SET) catalysed by $[\text{Ru}^{\text{II}}(\text{bpy})_3]^{2+}$ complex **39** in mouse erythrocytes. Labelling of carbonic anhydrase (CA) by using a benzene sulfonamide-conjugated Ru photocatalyst and a biotin *N*-modified tyrosyl radical trapping agent.⁵¹

the intracellular EGFR level without affecting other proteins (such as Akt, PkC α , tubulin and actin). The $^1\text{O}_2$ -mediated oxidation of EGFR residues likely leads to cross linking of the

protein with other proteins or to the oligomerisation of the EGFR, as suggested by the observation of a ladder of bands of higher molecular weights by immunoblotting analysis with an




Fig. 16 Ru-gefitinib photocatalyst **41** reported by Nakamura *et al.* for targeted knockdown of the epidermal growth factor receptor (EGFR) protein within A431 cells.⁵²






Fig. 17 Photo-induced azide-thioalkyne cycloaddition promoted by ruthenium(II) complexes **34** and **42–43** in HeLa cells.⁵³

anti EGFR antibody. The addition of TRT in the cell medium resulted in the recovery of the labelling properties of the $[\text{Ru}^{\text{II}}(\text{bpy})_3]^{2+}$ type complex **41** along with the inhibition of its knockdown properties.

In 2021, Mascareñas and co-workers reported a series of ruthenium-arene sandwich complexes **34**, **42** and **43** able to catalyse azide-thioalkyne cycloadditions (RuAtAC) under UV light irradiation at 365 nm in biorelevant media such as PBS buffer, cell culture milieu (DMEM) and *HeLa* cell lysates (Fig. 17).⁵³ Complex **34** can be used as a precatalyst to perform RuAtAC even at diluted concentrations (250 μM). This method was used to modify peptides and oligonucleotides having an azide function by reaction with thioalkyne-substituted molecules. Using this strategy, a fluorophore such as rhodamine was introduced on a DNA fragment. Furthermore, experiments were performed in DMEM-HEPES containing *HeLa* cells, by mixing thioalkyne, azide, and ruthenium catalysts (with irradiation for

15 min). After cell treatment, the cyclisation product was observed both in the extracellular media and in the cellular content. However, the authors considered that it is likely that at least part of the product internalises after being formed. We note that, in 2012, Meggers *et al.* used also the ruthenium complex **34** to perform the cleavage of allylcarbamates inside *HeLa* cells, suggesting that the reaction could take place inside cells.

The development of photocatalysis allowed the reaction spectrum available by Ru catalysts to be broadened even further. The use of azides that can be photoreduced or coupled with an alkyne in a dipolar cycloaddition has been of particular interest. The spatial and temporal addressing that is brought about by the use of light as the trigger is of course a key feature of these transformations, which can be as diverse as protein modifications with exogenous substrates or photodynamic therapy using endogenous oxygen.




Fig. 18 Structures of Ir^{III} complexes **44–45** inducing ROS production inside cancer cells and proposed reaction pathways for ROS generation and activation/deactivation of Ir complexes **44–45** inside mammalian cells.⁵⁸



3. Iridium

Iridium complexes have been found to have very interesting properties as anticancer agents and photosensitizers for photodynamic therapies.^{54–57} Furthermore, some iridium(III) complexes can interact with intracellular NAD(P)H to form hydride complexes. This feature was exploited by several research groups to develop Ir^{III}-based catalytic and photocatalytic systems in normal and cancer cells to unbalance cell redox equilibrium through the generation of reactive oxygen species (ROS) or to reduce carbonyl functions on organic substrates. Furthermore, the properties of some Ir^I complexes to generate η^3 -allyl intermediates have been exploited in cells for decaging allyloxycarbonyl-protected profluorophores and prodrugs in the presence of nucleophiles such as GSH.

3.1 Catalysis

In 2014, Sadler and coworkers reported two organoiridium(III) complexes **44–45** able to increase the level of reactive oxygen species (ROS) inside cancer cells (Fig. 18).⁵⁸ Their anticancer

activity against human ovarian A2780 cancer cells was first tested. An IC₅₀ of 120 nM was measured for complex **45**, which was found to be 6 times more active than the complex **44** and almost 10 times more than cisplatin against this cell line. A screening of the anticancer activity on approximately 60 human cancer cell lines showed that complex **45** exhibited a high efficiency against a wide range of cancer cells. By using the NCI COMPARE algorithm, which quantitatively compares the selectivity for cancer cells of a compound to a database, no correlation was observed between the Ir^{III} complexes **44** and **45** and reported platinum complexes, suggesting a different mode of action. A reaction pathway was proposed, in which the initial complexes **44–45** are hydrolysed into active [Ir^{III}(OH₂)⁺] species, which can then perform redox catalysis in cancer cells by hydride transfer from NADH to iridium and then to dioxygen (Fig. 18). Ir^{III} complexes **44–45** can be deactivated by reaction with GSH at different rates, complex **45** being less sensitive to deactivation. By using an inhibitor of γ -glutamylcysteine synthetase to decrease the GSH concentration, an increase of ROS was observed by flow cytometry, which could be correlated with an increase of anticancer activity of **44–45**.

In 2017, Do and coworkers designed an iridium(III) catalyst **46**, which can perform hydride transfer from NADH to aldehydes, inside NIH-3T3 mouse embryo fibroblast cells, to generate alcohols (Fig. 19).⁵⁹ The reaction was monitored inside cells by using a fluorescent probe Bodipy-CHO **47** presenting visible light absorbance ($\lambda_{\text{max}} = 480$ nm) and having a reduced form (Bodipy-CH₂OH, **48**), which is about five times more emissive than the aldehyde. Fluorescence enhancement was observed when incubating the cells with both the probe and the complex, indicating the successful reduction of the probe, whereas control experiments (Bodipy-CHO without **46**) showed no effect. Moreover, the morphologies of the cells after exposure to complex **46** and cytotoxicity studies showed that **46** was nontoxic at the concentration used (20 μ M). The need for NADH




Fig. 19 Hydride transfer reaction catalysed by Ir^{III} complex **46** inside NIH-3T3 mouse embryo fibroblast cells inducing intracellular fluorescence enhancement.⁵⁹




Fig. 20 (A) Allylcarbamate (Alloc) cleavage reactions by Ir^I complexes **49–51** used in PBS buffer and (B) within HeLa cells for decaging of protected rhodamine (R = Alloc).⁶⁰



to perform the reaction was studied by using sodium pyruvate to inhibit NADH generation. Under these conditions, no fluorescence enhancement was observed, clearly indicating that no reaction can take place without NADH.

In 2021, Sasmal and coworkers reported organoiridium(III) complexes **49–51** (Fig. 20) capable of cleaving allyloxy carbonyl (Alloc)-protected amines **52** in phosphate-buffered saline (PBS) in the presence of GSH. The reaction also occurs in the HeLa cell lysate, and inside *HeLa* cells using the Ir^I complex **51**, without any other exogenous agents (Fig. 20A).⁶⁰ Within *HeLa* cells, the catalyst was shown to be active for the cleavage of Alloc groups on protected rhodamine **2** (Fig. 20B), which once decaged into **3** is fluorescent, and for the decaging of the Alloc-protected doxorubicin anticancer prodrug **5**. The iridium complex **51** was found to be non-cytotoxic at 20 μM and to exhibit a long period of activity, suggesting negligible

deactivation in the biological medium. Inductively coupled plasma mass spectrometry (ICP-MS) showed high Ir accumulation in the cytosol, suggesting that the reaction mostly occurs in the cytoplasm. The nature of the ligand L was found to be important. For instance, complex **49** was found to be inactive, which can be explained by the hydrophobicity of PPh₃, leading to low solubility in water. Furthermore, the authors suggested that the bulky structure of PPh₃ could cause steric hindrance, impeding substrate binding.

Although there are fewer examples than with Ru, Ir complexes can also catalyse uncaging reactions without the need to add external nucleophiles for deprotection. It is quite noteworthy that these complexes can react with endogenous biomolecules such as NADH to exert their catalytic activity (e.g., ROS production or alcohol oxidation). Alleviating the need to add exogenous reagents is indeed very promising for future medical applications.

3.2 Photocatalysis

In 2019, Gasser, Chao, Sadler and coworkers reported a photocatalytically active iridium(III) complex **53** catalysing photoredox oxidation of NADH within several cancer cell lines such as *NCI-H460*, *HeLa*, *HepG2* and *SGC-7901* under visible light irradiation ($\lambda = 450 \text{ nm}$ or 465 nm). Complex **53** was found to be active both under normoxia (20% O₂) and hypoxia (1% O₂), where photochemotherapeutic agents used in PDT are usually less effective. The authors showed that the light-activated Ir^{III*} catalyst acted as a strong oxidant, able to generate NAD[•] radicals through direct oxidation of NADH. Under hypoxia, cytochrome *c* (Fe³⁺, Cyt *c*_{ox}) acted as a co-oxidant to regenerate Ir^{III} from Ir^{II} in the catalytic cycle but also to form NAD⁺ from NAD[•] (Fig. 21).⁶¹ This induces an imbalance of cell redox equilibrium, leading to cell death. In cells, **53** was found to mainly localise in mitochondria. In the dark, **53** was found to be nontoxic for cells at the active concentrations used, an important property to reduce the side




Fig. 21 Photoredox Ir^{III}-based catalytic cycle proposed by Sadler *et al.* for in cellulo light-induced NADH oxidation under hypoxic conditions.⁶¹




Fig. 22 Biocompatible Ir^{III} complex **54** developed by Huang *et al.* and proposed photoredox Ir^{III}/Ir^{IV}-based catalytic cycle for in cellulo light-induced ROS generation and NAD(P)H reduction in the presence of O₂.⁶²



effects of therapeutic treatments. **53** was also found to be photostable under visible light irradiation. Finally, **53** was shown to be active toward A549 lung cancer multicellular spheroids of ~800 μm diameter after two-photon irradiation (760 nm), thus demonstrating its potential for the treatment of large or deep-seated tumours. By comparison, 5-ALA (a photosensitizer precursor) and cisplatin, used as controls, did not present any photocytotoxicity on the same tumor models.

In 2021, Huang *et al.* presented an organoiridium(III) photocatalyst **54** with a coumarin-based ligand, which exhibits excellent biocompatibility (Fig. 22).⁶² *In cellulo*, **54** was found to be active after visible light irradiation ($\lambda = 465$ or 525 nm) and to allow the oxidation of NADPH and amino acids *via* single electron transfer (SET) with a high turnover frequency. The photo-induced oxidation reaction imbalances cell redox equilibrium by oxidising³⁴ NAD(P)H and generating ROS. It also induces changes in mitochondrial membrane potential, leading to necrosis and apoptosis of cancer cells. **54** was found to be nontoxic towards both normal and cancer cells in the dark but is highly cytotoxic after light exposure towards cancer cells including sorafenib-resistant (HepG2-SR) and cisplatin-resistant cells (A549R). In HepG2 cells, **54** was found to be three times less active under hypoxia (5% O_2) than under normoxic conditions (20% O_2), showing the important role of O_2 in the mode of action. In contrast to previously described Ir^{III} photocatalysts, it was proposed that the Ir^{III} catalyst acted as a strong excited-state reductant, leading to direct intracellular $\text{O}_2^{\cdot-}$ production from O_2 . The Ir^{IV} intermediate is then reduced to Ir^{III} by NAD(P)H to close the catalytic cycle, generating NADP⁺ (Fig. 22). Due to its hydrophilicity, the cellular uptake of **54** was

found to be low (in CNE-2Z cells) but to be enhanced after photoexcitation, leading to a distribution both in the lysosome and mitochondria, determined by confocal microscopy without washing before irradiation. The photocatalytic system was shown to be highly biocompatible *in vivo* inducing no damage to tissues in zebrafish embryos in the dark. Finally, **54** showed light-induced activity against a mouse CT26 colon carcinoma model with a significant decrease of the tumor volume and weight after light irradiation (465 nm).

Iridium photocatalysis has been developed very recently and so far only for photodynamic therapy purposes. In this setting, the possible reaction with NADH greatly improves the therapeutic scope of these complexes as they can thus be applied in hypoxic environments.

4. Palladium

Palladium is a prime metal for organometallic catalysis, and it is therefore logical that it has been investigated for *in cellulo* systems. Homogeneous and heterogeneous systems have been used. For instance, palladium-based bond cleavage catalysis in living systems was performed by using Pd nanoparticles,²⁰ which operate in the extracellular medium. Such approaches require implanting Pd resins on the reaction site. Cleavage reactions catalysed by heterogeneous catalysts can also be induced inside cells but encountered some issues such as poor cellular uptake, poor solubility, or instability of the Pd nanoparticles under biological conditions. Therefore, various well-defined Pd^{II} and Pd^0 complexes have been tested for intracellular “homogeneous” catalysis. Examples of cross-coupling




Fig. 23 (A) Copper-free Sonogashira cross-coupling reaction inside *E. coli* for fluorescent labelling of HPG-Ub protein by modified fluorescein using a discrete Pd^{II} precatalyst. (B) Sonogashira cross-coupling labeling of Myoglobin inside *E. coli*.^{65,66}



reactions have been reported in bacteria and on a mammalian cell surface.^{63–65} However, the main applications of discrete Pd complexes lie in allyl, propargyl and allenyl cleavage reactions for prodrug and profluorophore activation as well as nitric oxide (NO) release in various types of cells. No photocatalytic application of Pd complexes have been reported to date to the best of our knowledge.

In 2011, Lin and coworkers reported a copper-free (Heck–Cassar) Sonogashira cross-coupling reaction in *E. coli* cells. The coupling reaction involved fluorescein iodide **55** and homopropargylglycine-encoded-Ubiquitin (HPG-Ub) with one HPG at its C-ter (Fig. 23A).⁶⁵ After screening of several palladium ligands to perform Sonogashira cross-coupling reactions in water, the robust aminopyrimidine/Pd^{II} complex **56** was selected for evaluation inside *E. coli*. HPG-Ub-overexpressing *M15A* cells were incubated with 1 mM of palladium complex, 100 μM of fluorescein iodide and 5 mM of sodium ascorbate in PBS buffer. After 4 h at 37 °C and after washing, cells incubated with the palladium complex showed green fluorescence under 365 nm excitation while the negative control (cells not incubated with the palladium complex) did not. This result was confirmed by SDS-PAGE after cell lysis, suggesting that the cross-coupling reaction takes place inside the bacteria. We note that this cross-coupling reaction requires incubation with 50 equiv. of the Pd complex per protein substrate to be efficient. Moreover, some level of toxicity was observed when cells were incubated with Pd^{II} complex **56** without preactivation, whereas with preactivation, no toxicity was observed. This preactivation consists in stirring for 1 hour before the addition of a mixture of the fluorescein iodide **55**, the Pd^{II} complex **56** and sodium ascorbate at 37 °C.

Later, in 2014, Lin and coworkers reported a Sonogashira cross-coupling reaction inside *E. coli* and on a mammalian cell surface involving an alkynyl-modified protein and an aryl-iodide using the Pd-based complex **56**.⁶⁶ *E. coli* *DH10B* cells, which express the modified myoglobin protein containing modified lysine bearing a butynyl group (**57**), were incubated with a solution of the active Pd complex **56** freshly preformed in

DMSO from Pd(OAc)₂, an aminopyrimidine ligand, fluorescein iodide **55** and sodium ascorbate (Fig. 23B). The C–C coupling reaction was monitored by in-gel fluorescence and SDS-PAGE of the modified protein (**58**).

In 2013, Chen and coworkers also developed a Sonogashira cross-coupling reaction between a green fluorescent protein (GFP) bearing an alkyne group **59** and a fluorophore (Fluor 525) linked to an iodophenyl group **60**, inside *E. coli* and pathogenic *Shigella* bacterial cells (Fig. 24).⁶⁷ The activity of twelve commercially available Pd complexes was studied, showing that Pd(NO₃)₂ was the most active catalyst. A ligand-free approach presents assets because the catalyst can be transposed from *in vitro* to *in vivo* catalytic reactions without looking at the ligand cell permeability. No loss of fluorescence was observed in the presence of Pd(NO₃)₂, suggesting no denaturation of fluorescent GFP. Similarly, the fluorescence of the more fragile protein luciferase remained intact in the presence of Pd(NO₃)₂, suggesting no denaturation. Moreover, Pd(NO₃)₂ can pass through the cellular membrane of *E. coli* and *Shigella* bacterial cells and was shown to be non-cytotoxic towards these cells at the concentration used (*C* = 200 μM), thus demonstrating its biocompatibility. However, comparison with previous results from the literature led the authors to suggest that the Pd(NO₃)₂-induced reaction might involve Pd nanoparticles that could be formed in the presence of sodium ascorbate. It is important to note that the use of Pd(NO₃)₂ allowed efficient coupling reactions to take place with only 2 equiv. of Pd per protein substrate. The catalytic system was applied to develop bioorthogonal labeling and tracking of toxin proteins in *Shigella* pathogens.

In 2014, Chen and coworkers reported that palladium complexes were able to induce cleavage reactions of allyl or propargyl carbamate groups inside cells such as *HeLa*, *HEK293T*, *NIH3T3* and *A549* cells.⁶⁸ The cleavage activity of a series of commercially available Pd⁰/Pd^{II}/Pd^{IV} precatalysts **62–67** was studied using the protected profluorophore **61** and the Alloc-protected rhodamine 2 as probes (Fig. 25). Pd(dba)₂ (**65**) (Pd⁰) and Pd₂(allyl)₂Cl₂ (**66**) (Pd^{II}) were found to be the most active complexes of the series and were both more active for




Fig. 24 Sonogashira cross-coupling inside *E. coli* or *Shigella* cells with Pd(NO₃)₂ as a precatalyst for coupling of fluorescent protein GFP with Fluor 525 and bioorthogonal labeling of toxin proteins in living pathogenic *Shigella* cells.⁶⁷






Fig. 25 Alloc and propargyloxycarbonyl deprotection of profluorophores by palladium complexes inside cells.⁶⁸

propargyl than allyl cleavage. The addition of an organic ligand (68–70) was found to decrease complex activity. In *HeLa* cells, complexes 65 and 66 were found to be non-cytotoxic at 10 μ M, while still being active. Moreover, the reaction could be performed on different proteins without denaturation. Pd₂(allyl)₂-Cl₂ (66) was also shown to be active inside *HeLa* cells for the cleavage of propargyl groups on modified proteins (such as GFP), protected by a propargyl group on a lysine residue as in 71. After the incubation of the cells with Pd₂(allyl)₂Cl₂ (66) and the modified protein, the propargyl cleavage was quantified by gel fluorescence through labeling of the unreacted protein using a click reaction, showing an efficiency of 31%. The authors suggested that the low yields could be correlated with low concentration of the protein of interest and of the nonspecific absorption of palladium complexes, leading to low effective catalyst concentration in cells. Despite this disadvantage, the Pd-mediated propargyl cleavage reaction was used for restoring the activity of inactive modified (enzymatic) proteins. For instance, in *Shigella* type III cells, a phosphothreonine lyase (OspF) induces the dephosphorylation of phosphorylated Erk (pErk). The mechanism involves Lys 134 as a residue. The substitution of this residue by propargyl-Lys (ProcLys) induces the loss of enzyme activity. The cleavage of the propargyl on ProcLys-134 by Pd(OAc)₂ (62) occurred with a yield of 28% within host cells (followed as before by gel fluorescence after the click reaction), inducing the restoration of over 80% of enzyme

activity compared to the wild type for pErk dephosphorylation. This process was shown to take place in the cell nucleus.

In 2016, Chen and coworkers reported the cleavage of allenyl groups on tyrosine residues on several proteins inside cells by using palladium complexes Pd(dba)₂ (65), Pd₂(allyl)₂Cl₂ (66), Pd(TPPTS)₄ (72) and Pd(TAPAD)₄ (73) (Fig. 26).⁶⁹ The bond cleavage reaction was studied *in vitro* on purified proteins and inside *HEK293T* cells. The authors showed that complexes 65, 66, 72, and 73 could catalyse the cleavage of a GFP modified with an allene group on the Tyr149 residue (GFP149AlleY) at a concentration of 10 μ M. Pd(TAPAD)₄ (73) was found to be the most active compound *in vitro*, whereas Pd₂(allyl)₂Cl₂ (66) was the most active in living cells. This difference of activity was linked to a difference in the cellular uptake of the complexes that was quantified by ICP-MS. Allenyl cleavage was also performed on other proteins inside *HEK293T* cells: Pd(dba)₂ (65) and Pd₂(allyl)₂Cl₂ (66) could rescue enzyme activity by cleaving allenyl groups on the tyrosine residue involved in enzyme activity. The activities of a phosphorylase (Src) and a protease (anthrax lethal factor) that had been inactivated were rescued by incubating cells with 20 μ M of complex 65 or 66.

In 2017, Bradley and coworkers developed a discrete organopalladium catalyst able to catalyse propargyl-cleavage of ProcRhodamine 61 inside human *PC-3* cancer cells.⁷⁰ Complex 74 is composed of an NHC ligand linked to a polycationic cell penetrating peptide (tri-lysine), which is itself bound to a Cy5






Fig. 26 Allenyl group cleavage on tyrosine residue inside HEKT297T cells to restore the activity of Tyr-dependent enzymes.⁶⁹




Fig. 27 Propargyl deprotection of a profluorescent probe by a discrete palladium complex inside PC-3 cancer cells. The ligand is linked to a polycationic cell penetrating peptide to favor cellular uptake.⁷⁰

fluorophore (Fig. 27). Inside cells, 74 is mainly distributed in the cytosol but was also detected inside the nucleus. This distribution was monitored by fluorescence thanks to the rhodamine probe. 74 showed a low cytotoxicity toward PC-3 cells: no cytotoxicity was observed even at 200 μM. For *in cellulo* catalysis, PC-3 cells were incubated with 30 μM of 74, the extracellular catalyst was washed, and 50 μM of Proc-rhodamine 61 was added. The formation of rhodamine 3 was verified by flow cytometry, indicating that 74 was catalytically active for the propargyl-cleavage of Proc-rhodamine 61 inside PC-3 cells.

In 2018, Huang and coworkers reported the use of Pd(dba)₂ as a biocompatible Pd⁰ catalyst to induce the bond cleavage of O²-alkyl-derived diazeniumdiolates 76–84 and release nitric oxide (NO), *via* the intermediate 75, inside living cells to control cell growth.⁷¹ O²-propargyl- (76–80), O²-allyl- (81) and O²-(4-alkoxybenzyl)-diazeniumdiolates (82–84) have been evaluated as substrates for intracellular N–O bond cleavage inside HCT116, A549, HL-60, and OVCAR5 cancer cells (Fig. 28). Cells were preincubated with 1 μM of Pd(dba)₂ and washed before incubation of 1 μM of the diazeniumdiolate derivatives (76–82).




Fig. 28 Cleavage of different protecting groups by Pd(dba)₂ inducing NO release in living cancer cells.⁷¹



Under these conditions, **76** and **78** were found to be the most efficient substrates to release NO, inducing significant inhibition of cell growth after 48 h in the presence of Pd(dba)₂ (**65**). Control experiments without Pd(dba)₂ (**65**) showed that the antiproliferative activity of **76/78** was *ca.* 17 times lower on *HCT116* and *A549* cells and even lower on human normal colonic epithelial cells (IC₅₀ = 68.1 μM for colonic cells compared to 27.2 μM and 33.9 μM, respectively, for *HCT116* and *A549*).

In 2018, Mascareñas and coworkers designed several palladium(II) complexes **87–92**, bearing a variety of N, S or P ligands, which were found to be catalytically active in water for the cleavage of propargyl protecting groups on a phenol derivative **85** (Fig. 29) or for an Alloc group deprotection on rhodamine **2**.⁷² The activity of the Pd^{II} complexes **87–92** was then tested in cell lysates and in living mammalian cells (*Vero* and *HeLa* cells). Catalysts bearing phosphine ligands (**89–92**) were shown to be the most active inside cells although the yields were still low for the propargyl and Alloc cleavage. This observation suggested a superior stability of the phosphine ligands in biological media (compared to N and S ligands). Moreover, the phosphine palladium complexes were found to have a superior cellular uptake, while being nontoxic at a concentration of 50 μM. Phosphine ligands are an asset in this study since they can be easily modified to modulate reactivity and cellular uptake or to target cells: a phosphonium group or a hydrophobic pyrene group can lead to a preferential accumulation of the catalyst in mitochondria.

In 2019, Bradley, Lilienkamp and coworkers reported the propargyl cleavage of an anticancer protected prodrug **93** inside *MCF-7* cells by the NHC-Pd^{II} catalyst **95** (Fig. 30).⁷³ Complex **95** showed a good activity at 10 mol% for the cleavage of propargyl-5-FU (5-pFU, **93**) in *MCF-7* cells after 24 h incubation with **93**. This cleavage reaction leads to the release of 5-FU (**94**), an anticancer drug. The Pd^{II} catalyst **95** was also found to be




Fig. 30 Propargyl cleavage of a prodrug inside *MCF-7* cells and in a tumor model using a well-defined NHC-Pd^{II} precatalyst.⁷³

catalytically active in a 3D cancer cell culture (cancer cell spheroids) for the cleavage of the propargyl group on 5-pFU **93**. In this case, the toxicity generated through the deprotection of the prodrug **93** by the Pd^{II} complex **95** was found comparable to that of the control experiment with 5-FU (**94**). The cleavage reaction occurred inside and outside the cells.

In 2022, Bernardes and coworkers demonstrated that O-protected or N-protected prodrugs and profluorophores protected by allyl ether or allyl carbamate groups could be deprotected in living cells using Na₂PdCl₄ as a simple source of water-soluble palladium(II) (Fig. 31).⁷⁴ Na₂PdCl₄ is a good candidate for intracellular uptake, better than the Pd⁰/TPPTS system employing a water-soluble phosphane ligand. The system was




Fig. 29 Propargyl cleavage on a profluorophore catalysed by well-defined palladium(allyl) complexes in *Vero* and *HeLa* cells.⁷²






Fig. 31 Allyl ether or allyl carbamate cleavage by a palladium complex inside SKBR3 cells.⁷⁴

shown to be operative in SKBR3 breast cancer cells. After pre-incubation with Na_2PdCl_4 , the cells were submitted to sodium ascorbate and then incubated with the substrates. The Pd^{II} precatalyst is reduced *in cellulo* to active Pd^0 species by sodium ascorbate (no decaging reaction was observed in its absence). The exact structure of intracellular catalytically active Pd^0

remains to be clarified, although kinetic studies suggest the contribution of nanoparticles in the reaction. The method was applied for *in cellulo* bioorthogonal cleavage of the allyl group on O-protected duocarmycin **97** and of the Alloc group on N-protected doxorubicin **6** (two anticancer prodrugs) inside SKBR3 breast cancer cells. In both cases, the cytotoxic activity of the




Fig. 32 Control of DNA binding based on a palladium-mediated uncaging process under mild and physiological conditions reported by Mascareñas *et al.*⁷⁵



free drugs **5** and **96** was recovered after sequential incubation with Na_2PdCl_4 and then sodium ascorbate.

In 2022, Mascareñas and coworkers reported a new approach for controlling DNA binding based on a palladium(0)-mediated uncaging process under mild and physiological conditions (Tris buffer). The authors designed a dimer, based on basic leucine zippers (bZIP) linked with a phenol derivative protected with a propargyl group **98**, which is cleavable on demand using Pd(allyl) precatalysts **66–90** (Fig. 32).⁷⁵ The propargyl cleavage of the phenol leads to a chain reaction, releasing the two monomers (Fig. 32). The dimeric form **98** has a good affinity for DNA unlike the monomer **99**. The binding of DNA could therefore be modulated by the addition of a Pd^{II} precatalyst. This on/off process has been performed under biological conditions but never *in cellulo* nor *in vivo*. Considering that this kind of propargyl-cleavage reaction has already been undertaken *in cellulo* with this family of Pd^{II} catalysts,⁹ the authors suggested that it was likely possible to be transposed in living cells.

The use of palladium complexes has greatly expanded the range of transformations that can be achieved *in cellulo*, making possible C–C cross-coupling reactions for instance. Considering that all the potential of the Pd-catalysed reactions has not been reached yet, considerable breakthroughs can be expected in the future. Within ten years, noticeable improvements have already been brought about regarding the catalyst loading, which was drastically reduced. However, it is still often difficult to unambiguously identify the active species (that could be palladium(0) nanoparticles) present in the cells.

5. Platinum

Platinum complexes have been widely used in organic chemistry but their application *in cellulo* as a catalyst is rare and limited by the toxicity of some Pt^{II} complexes. However, Pt^{IV} complexes are less toxic and can be designed bearing

a photosensitizer (Riboflavin or Pyropheophorbide) able to perform photoreduction of Pt^{IV} in Pt^{II} within cells inducing the targeted release of cisplatin (CisPt) or analogs.^{76,77} Recently, Bernardes and coworkers reported a bond cleavage reaction of pentynoyl amides and *N*-propargyl groups by using platinum catalysts (K_2PtCl_4 and CisPt) to release secondary amines from stable tertiary amides (Fig. 33).⁷⁸ This reaction was used to release the anticancer agents monomethyl auristatin *E* (MMAE) and 5-pFU from the protected precursors **100** and **93**, respectively, to induce cytotoxicity in mammalian cell cultures. Unfortunately, it turned out that CisPt was too toxic at the concentration required for catalysis ($C = 2.5 \mu\text{M}$). In contrast, K_2PtCl_4 was found not to affect *HeLa* cell viability at concentrations below 50 mM, where catalyst loading is still efficient. The incubation of *HeLa* cells with K_2PtCl_4 and the prodrugs induces a two-fold increase in toxicity compared to control experiments with a non-decaging derivative or with 5-pFU **93** alone. In a colorectal Zebrafish xenograft model, this system induced a decrease of tumor sizes. Note that the presence of a nucleophile (such as glutathione) was found to lower the reaction rate even if the catalyst remained active. To overcome these issues, the team suggested the use of platinum nanoparticles or the optimisation of the complexes with new organic ligands to limit the deactivation.

In 2020, Huang and coworkers proposed a solution to overcome the platinum toxicity issue by developing a Pt^{IV} catalyst **102** covalently linked to an O^2 -propargyl diazeniumdiolate moiety, which is non-toxic toward normal cells but is reduced in cancer cells by cytoplasmic reductants to form a Pt^{II} species.⁷⁹ This reduction releases CisPt and O^2 -propargyl-caged diazeniumdiolate **103** (Fig. 34). Unlike Pt^{IV} , Pt^{II} catalyses the cleavage of O^2 -propargyl, leading to the release of NO donor **104** and finally NO. NO donors were previously studied for their antiproliferative properties against cancer cells and were found to have potential as cancer therapeutic agents. The Pt^{IV} complex




Fig. 33 Pentynoyl and propargyl amine deprotection of prodrugs by platinum(II) complexes inside *HeLa* cells.⁷⁶






Fig. 34 O^2 -propargyl cleavage and NO release inside A2780 cells using a platinum(IV) precatalyst of low toxicity.⁷⁹

102 was shown to induce O/N propargyl bond cleavage in various molecules, under biocompatible conditions, in good yields and with high efficiency. The simultaneous release of CisPt and NO induces selective and synergistic anticancer activity *in vivo*.^{80–83} Pt^{IV} complex **102** enters the cells and has a higher toxicity against human ovarian cancer A2780 cells compared to normal IOSE80 epithelial human cells. This strategy is flexible and could be used to degrade other molecules of interest for several biological applications.

While platinum salts are part of the WHO Essential Medicine List, or maybe because of this, their *in vivo* applications as catalysts remain rather scarce. This can also be due to the harsh conditions (such as prolonged heating) that are usually required for platinum catalysis to be efficient, which makes it, in most cases, inapplicable for biological applications.

6. Gold

While metallic gold is biocompatible, gold salts are well-known to be cytotoxic, and therefore the development of ligands to prevent their toxicity is essential. Nevertheless, Au^I and Au^{III} salts are also notoriously alkynophilic and triple bonds are very useful biorthogonal functions. Therefore, using Au^I or Au^{III} -based catalysts to react with alkynes inside cell is a very attractive strategy.

6.1 Catalysis

As Au^{III} is cytotoxic,⁴ the first work involving this salt in an *in cellulo* catalysis was aimed to detect traces of Au^{III} through a reaction that it would specifically catalyse. A series of systems were studied based on the same principle: the generation of a fluorescent probe upon reaction with Au^{III} . For instance, rhodamine derivative **105** was synthesised and incubated in *HaCaT* cells. Without gold(III) salts, no fluorescence was




Fig. 35 Generation of fluorescence inside *HeCaT* cells by the generation of **106** after incubation with Au^{III} .^{84,85}

observed, while upon addition of $AuCl_3$ or $HAuCl_4$, the products rearranged into a fluorescent molecule **106** (Fig. 35).^{84,85}

The same principle has been used with other fluorophores like Bodipy⁸⁶ or coumarins. Hence, Kim and co-workers developed a system based on an *apo*-coumarin **107** that is not fluorescent but upon a hydroarylation reaction selectively catalysed by $AuCl_3$ the fluorescence is turned-on with the formation of coumarin **108**.⁸⁷ To determine the probe sensitivity, the emission spectra of a solution of the *apo*-coumarin **107** at several concentrations of Au^{III} were investigated. The limit of detection of the probe was determined to be 64 ppb (parts per billion), which meant that the probe was relevant for biological applications since 40 ppm of Au^{III} are necessary to be strongly toxic (90% cell death) towards K562 human cells. Fluorescence imaging was successfully performed in *HaCaT* cells, with 10 μM of Au^{III} and 50 μM of the coumarin precursor **107** (Fig. 36). A blank experiment also confirmed that the presence of both the Au^{III} and molecule **107** was necessary to obtain fluorescence. Interestingly, in this case, the Au^I complex, Ph_3PAuCl , did not induce the turn-on of the fluorescence.

To perform the same reaction using Au^I complexes, Mascareñas and co-workers used $AuCl$ complex **109** bearing a water-soluble ligand.⁸⁸ The cytotoxicity of the Au^I catalyst **109** as well as the colourless compound **111** and the green/blue product **113** were tested in *HeLa* cells. None of them showed significant toxicity individually. Reactivity tests were carried out in *HeLa* cells incubated with 50 μM of the $AuCl$ complex **109** and 100 μM of the colourless substrate **111**. Fluorescence developed in the cells incubated with both compounds. The authors also tested the capacity of different gold catalysts to enter cells. The cellular uptake of the complexes varied greatly depending on the ligands. Au^{III} complexes without the cage-like ligand of **109** have a much higher concentration inside cells but a lower catalytic activity, while the complex **109** has a considerably better




Fig. 36 Gold(III)-catalysed hydroarylation of non-fluorescent **107** into a fluorescent coumarin.⁸⁷






Fig. 37 Simultaneous Au^I and Ru^{II} catalysis inside *HeLa* cells. Gold-catalysed hydroarylation and allyl-deprotection catalysed by Ru.⁸⁸

catalytic performance. They also showed that this reaction could be achieved orthogonally compared to other metal-based catalysis, in particular ruthenium promoted allyl cleavage (Fig. 37). Cellular tests carried out in the presence of substrate **111** and **112** as well as the AuCl catalysts **109** and the ruthenium catalyst **110** revealed infrared fluorescence coming from product **114** and green and blue staining coming from product **113**. Cross experiments also revealed that the ruthenium catalyst **110** could not promote the hydroarylation of **111** and the gold complex could not induce decaging of **112**. This is an example of two biorthogonal reactions that are successful and compatible inside living cells.

To avoid the cytotoxicity of AuCl, Mascareñas used a specific phosphine water soluble ligand. To use other ligands, such as NHCs, whose complexes with Au^I are known to be cytotoxic, Zou and co-workers developed an *in situ* activation strategy for NHC–Au^I complexes.⁸⁹ The idea was to use NHC–Au^I–alkyne complexes such as **115**, which are known to be unreactive with thiols and therefore non-cytotoxic. The authors confirmed their stability with bio-relevant thiols. They next studied a NHC–gold–alkyne complex as a trans-metalation agent on a Pd complex. A series of Pd^{II} complexes were used and appeared to undergo transmetalation both in organic and aqueous solvents. A mixture of NHC–gold complex **115** and Pd^{II} salts in a buffer was also shown to induce the hydroarylation, already used before, to afford a fluorescent coumarin. For instance, NHC–Au complex **115** induced transmetalation on Pd(OAc)₂ to eventually form Pd⁰ and NHC–AuOAc **116**, which in turn catalysed the hydroarylation of **111** into fluorescent **113** (Fig. 38). Finally, this mixture was used to induce fluorescence inside A549 cancer cells and in zebrafish. The authors showed that only the mixture of the three components of the reaction, the NHC–Au **115** Pd

complex and the coumarin precursor, induced a significant increase in fluorescence, demonstrating that the transmetalation/hydroarylation sequence was at play *in cellulo* and *in vivo*. It is worth noting that if the gold complex seems non-cytotoxic in a short period of time necessary for the reaction, longer incubation times induce cytotoxicity and angiogenesis perturbation in zebrafish. Therefore, this bimetallic strategy was also used to activate the cytotoxicity of the gold complex in targeted cells. It is also clear from this example that ligand design is essential to obtain gold catalysts, which are both reactive and non-toxic.

To apply gold catalysis within fully developed living animals, Tanaka and co-workers developed a gold complex conjugated to a protein capable of catalysing an amide bond formation.⁹⁰ Gold is used here to activate a propargyl ester to convert it into an amide. The authors showed that the presence of the gold catalyst **117** was necessary for the coupling of ester **118** with amine **119** (Fig. 39A). To target specific organs, the gold complex was conjugated to a coumarin that binds strongly to albumin forming complex **120**. The albumin used here is heavily *N*-glycosylated with two types of oligosaccharides for liver targeting (Fig. 39B). The complex *N*-glycoalbumin/coumarin-gold was then studied. Two different compounds were tested, each having a different targeting glycan, as described in the team's previous work:⁹¹ Glyco-Au (Sia) with $\alpha(2-6)$ -disialoglycans targets the liver and galactose-terminated glycans Glyco-Au (Gal) targets the intestines. *In vivo* tests were carried out on live nude mice. After injecting Gluco-Au systems in the mice, fluorescent propargyl ester probes were administered (Fig. 39C). The glycoalbumin system provided a targeted delivery of the Au^{III} complexes within the first 30 min. A selective labelling was revealed by the amide bond formation between the amines






Fig. 38 Pd^{II}-triggered transmetalation activates Au^I compound **115** and induces hydroarylation of the coumarin precursor to form a fluorescent coumarin in A549 cancer cells and zebrafish.⁸⁹




Fig. 39 (A) Cyclometalated Au^{III} complex **117** structure and reactivity. (B) Preparation of glycoalbumins as "transition-metal carriers" to produce glyco-Au complexes. (C) *In vivo* fluorescence labelling by **120**-catalysed amide bond formation between propargyl ester-based imaging probes and surface.⁹⁰



present at the surface of the targeted organs and the fluorescent ester probes. This system is very promising as it functions on living animals, but the cytotoxicity of the gold complex is not discussed here and should probably be investigated before further applications.

Compared to platinum, gold catalysis generally requires milder conditions, making it more adequate for biological applications. In general, the reactions involve the π -activation of a triple bond, which grants them high potential for bio-orthogonal transformations and many developments are bound to follow these seminal studies. It is worth reminding that a gold complex (Auranofin) has been an approved drug, for rheumatoid arthritis, since 1985.

6.2 Photocatalysis

There has been no *in vivo* photocatalysis involving gold described in the literature so far. In 2020, Zou *et al.* described photoactivatable gold drugs,⁹² where they take advantage of the inactivity of Au-hydride complexes and their capacity to bind to thiols under irradiation. As the dissociation of the hydride ligands only occurs when the compounds are irradiated by visible light, they exhibit a promising photo-activated cytotoxic activity. However, no catalytic reaction is involved in the process.

7. Copper

Copper(I)-catalysed azide-alkyne cycloaddition (CuAAC) has gained tremendous attraction for biological applications. This reaction connects a terminal alkyne and an azide to form a triazole and serves as a standard example of click chemistry.⁹³ It is an improved version of Huisgen cycloaddition that requires high temperatures and pressures. Sharpless and Meldal found that by using Cu^I as a catalyst it was possible to achieve much better reaction rates under milder and more achievable reaction conditions (Fig. 40).^{94,95} Its applications are extremely varied and include chemical biology, in particular by Bertozzi.⁹⁶

Yet, the classic CuAAC has some major disadvantages in terms of biorthogonality. It is generally incompatible with thiols which are abundant inside cells. The CuAAC catalysts are usually deactivated by common cellular thiols. The major limitation is the reactivity and high toxicity of Cu^I ions. To overcome these drawbacks, researchers developed Cu^{II} catalysts that can be introduced into living organisms at a high concentration and then reduced to Cu^I. However, this is not a perfect solution, as many reducing agents are often not biocompatible either. In 2011, Sletten and Bertozzi described one of the most elegant solutions: a copper-free click reaction.⁹⁷ They found that while linear alkynes were unreactive at physiological temperatures, cyclooctynes easily reacted with azide-labeled proteins or glycans. They successfully improved the reaction rates by




Fig. 40 CuAAC reaction.

adapting the cyclooctyne structure. In this metal-centered review, we focus on how other approaches were developed to implement biorthogonal CuAAC reactions with interesting biological applications.

7.1 Catalysis

Cai and co-workers investigated in 2017 the effect of tris(triazolylmethyl)amine-based ligands on the CuAAC reaction performed inside living cells, using a biotin-coumarin-azide derivative as a probe (Fig. 41A). The alkyne partner consisted of proteins that were metabolically modified to incorporate homopropargyl glycine (HPG).⁹⁸ The coumarin moiety plays the role of a fluorogenic indicator, whilst the biotin moiety is an additional handle for other type of labelling (for example with fluorescein) *via* biotin-avidin interactions. Cell penetrating peptide Tat was attached to the ligand to enhance the efficiency, while avoiding the cytotoxicity of copper to make the Cu^I catalyst **121**, produced *in situ* by copper sulphate and sodium ascorbate. The authors indeed observed that cell viability was higher in the presence of the ligands compared to the cells that were incubated with only Cu^I, even though the proliferation was slower than that of the control cells, without a ligand or Cu^I. *In cellulo* reactions were performed on HPG-incorporating *HUVEC* and *OVCAR5* cell lines and the best results were obtained for a ligand modified with the Tat peptide that facilitates cellular uptake. The cell viability remained above 75% and the efficiency of the reaction varied between the cytosol and the membrane. Yields were measured using a fluorogenic reaction assay. The standard for the 100% yield was measured by dissolving the membrane proteins with SDS, meaning that all alkyl groups of the cell were converted to an HPG-containing group. However, for live cell tests, only the HPG groups present at the cell membrane were available for the reaction. Therefore, the yields measured for reactions taking place on the membrane surface are considered to be underestimated. On the membrane surface, the yield could reach up to 18%, while in the cytosol only 0.8% could be achieved. This was attributed to the presence of thiols such as GSH inside the cytosol, which hindered the reaction.

One year later, Mascareñas and co-workers developed a discrete copper(I) catalyst **122** using the same tris(triazolylmethyl)amine-based ligand BTTE (Fig. 41B).⁹⁹ In this study, the compound is capable of catalysing intracellular CuAAC annulations between two exogenous and freely spreading substrates without the need for sodium ascorbate. The reaction was performed between 9-(azidomethyl)anthracene, that has almost no fluorescence, and an alkyl, to produce the fluorescent triazole **123**. Tests were performed on HeLa and A549 cells, incubated with 50 μM of the copper catalyst **122**, 100 μM of the azide and 200 μM of the alkyne. For this specific compound, no sodium ascorbate was necessary to assist with the reactivity. After 60 minutes, the researchers could observe blue fluorescence across the cytoplasm and unaltered morphology of the cells.

Later, in 2021, Mascareñas and co-workers performed a metal carbene transfer reaction inside mammalian cells. They






Fig. 41 (A) *In cellulo* CuAAC reaction between coumarin/biotin azides and HPG-incorporating proteins.⁹⁸ (B) *In cellulo* CuAAC reaction that produces a fluorescent probe without the use of sodium ascorbate.⁹⁹

demonstrated how Cu^{II} catalysts could promote the intracellular cyclisation of alpha-keto diazocarbene **124** with *ortho*-amino arylamines *via* an N-H carbene insertion.¹⁰⁰ They chose to study the reaction with diaminonaphthalene **123**, which can form easy-to-monitor fluorescent benzoquinoxaline products **125–126**. After testing different metals, it was concluded that the $\text{Cu}(\text{OAc})_2$ catalyst gave the best yield, even at a 1 mol% loading. Preliminary tests of the reaction were carried out under different biologically relevant conditions to confirm its biorthogonality. Curiously, the authors noticed that when performed in PBS, the reaction tolerates certain biomolecules better such as

glutathione. They suggested that the buffer accelerated the targeted reaction due to its hydrophobic effects and disfavoured the formation of inactive Cu complexes. Finally, the reaction was carried out in *HeLa* mammalian cells. The authors confirmed that the diamine **123** presented a very low emission when excited at 385 nm while product **125** displayed high fluorescence (Fig. 42). After 1.5 h of incubation, fluorescence was observed in the cytosol, due to the production of the product **125**, as confirmed by mass spectrometry. To broaden biological applications, the authors investigated the synthesis of the toxic compound **126** in *HeLa* cells. This compound, also referred to as






Fig. 42 Copper-catalysed metal carbene transfer reaction in *HeLa* cells for the assembly of quinoxalines such as the fluorescent compound **125** and the toxic compound **126**, capable of inducing mitochondrial fragmentation.¹⁰⁰

Tyrphostin AG1385, promoted a decrease in the cell viability of 40% after 12 h of incubation at 50 μM . Compound **126** is known to provoke mitochondrial fragmentation, which suggests that the decrease in cell viability is a consequence of the reaction having been successfully carried out inside the cells, resulting in cell death (Fig. 42).

More work has been performed with *in vivo* copper catalysis focused on nanoparticles, which fall out of the scope of the present review, but that should nonetheless be cited for completeness. In 2016, Zimmerman *et al.* developed Cu^{I} -containing nanoparticles that can catalyse the CuAAC click reaction in bacteria and mammalian cells.¹⁰¹ The Cu^{I} catalyst is then generated *in situ* with sodium ascorbate acting as a Cu^{II} reducer. That same year, Bradley and co-workers described the use of entrapped copper nanoparticles (E-Cu-NPs) imbedded in a polymeric support as a biocompatible catalyst for the same reaction.¹⁰² They demonstrated that these E-Cu-NPs could be used as catalysts for the cycloaddition of two benign components to make a Combretastatin A4 analogue *in situ*, a potent anticancer drug.

Copper is an abundant first-row transition metal, which is much cheaper than previously mentioned metals. With copper catalysis, new click and carbene insertion reactions were developed and reported. However, copper can easily access different oxidation states, making unwanted toxicity difficult to control. Moreover, the shift between oxidation states can also disturb the catalysis and requires sterically hindering ligands to protect and stabilize the copper centre.

7.2 Photocatalysis

The only *in vivo* photocatalysis described involving copper investigates the use of mesoporous carbon nanospheres, which also fall out of the scope of the present review. Ren and Qu described the use of near infra-red light and photothermal conversion to promote an *in vivo* Cu^{I} catalysed azide-alkyne 1,3-cycloaddition (CuAAC) reaction.¹⁰³

8. Iron

Examples of *in vivo* application of artificial iron-based catalysts are scarce. Meggers and co-workers identified in 2012 an iron(III) $[\text{Fe}(\text{TPP})\text{Cl}]$ complex **127** as an efficient catalyst for *in cellulo* reduction of aromatic azides to amines (Fig. 43A).¹⁰⁴ Aromatic amines are useful functional groups in drugs and thus the *in situ* reduction of azides has shown some promise as a prodrug activation process.^{105,106} The authors first studied the reaction under biologically relevant conditions and in living mammalian cells. Compound **127** was administered to *HeLa* cells and its azide-reduction capabilities were followed by fluorescence microscopy, using a profluorophore of rhodamine 110 **128**. More specifically, cellular fluorescence was monitored by live-cell imaging with a confocal fluorescence microscope. *HeLa* cells




Fig. 43 (A) Structure of a 5,10,15,20-tetraphenyl-21*H*,23*H*-porphine (TPP)-containing complex, $[\text{Fe}(\text{TPP})\text{Cl}]$. (B) Iron-mediated reduction of a rhodamine 110 derivative to form fluorescent rhodamine 110. (C) Reduction of the azide molecule **129** to the anticancer drug candidate MS-275.¹⁰⁴



were pre-incubated with 100 μL of the non-fluorescent rhodamine azide **128** for 25 min and subsequently treated with 10 μL of $[\text{Fe}(\text{TPP})\text{Cl}]$ (Fig. 43B). The production of rhodamine 110 **3** inside cells was demonstrated within the first 10 minutes, with a 28-fold fluorescence increase observed. The authors also showed that the catalyst **127** successfully reduced the inactive compound **129** to form the anticancer drug candidate MS-275 **130** (Fig. 43C). However, *in vivo* experiments in *C. elegans* nematodes and *D. rerio* zebrafish did not prove so successful, as rhodamine 110 **3** fluorescence was detected prior to catalyst $[\text{Fe}(\text{TPP})\text{Cl}]$ addition. In both cases, strong fluorescence was observed after 20 to 30 minutes of incubation, the catalyst addition being redundant.

Even though iron is as abundant and cheap as copper, it is not as toxic, which makes it even more interesting for biological purposes. However, most of the reactions that have been reported with iron complexes rely on their Lewis acidity, which makes it difficult to transpose them in a biological environment. Yet, as shown above, it is possible to achieve *in vivo* iron catalysis and we believe that this could certainly be a promising field in the future.

9. Conclusion and prospects

Metal-promoted catalysis within cells with a discrete metal complex and an exogenous substrate is a challenge due to the presence of high concentrations of diverse nucleophilic species such as thiols or amines, which can deactivate the catalyst. In addition, the catalyst must be active even at diluted concentrations and have good biocompatibility and cellular uptake. Despite these significant challenges, important breakthroughs in the field have been achieved over the past few years, as described in this perspective. These advances have mainly revolved around improving the biocompatibility of the catalysts, the turnover, the catalytic loading and finally the reaction rates to avoid catalyst deactivation. Improvements to the catalyst were mainly achieved by caging the catalyst and having an *in situ* release of the metal complex, by activation of the complex with other components present only in the target organisms or even by targeted delivery to the membrane by using cofactors and their affinities. The use of light to activate the compounds allows having a locally specific reaction. The possibility to tune the wavelength of absorption by changing the metal ligands is another tool for depth specificity. However, the use of light can be limited by the localisation of the target area. Deep tissues are less accessible to light-induced activation. Moreover light itself can be toxic towards tissues, if it is close to UV wavelengths.¹⁰⁷

Heavy noble metals such as ruthenium, iridium, platinum and palladium are a scarce natural resource and complicated to extract. In contrast, first row metals such as zinc, copper, cobalt and manganese are essential for life and already present in the human body.¹⁰⁸ This is a reassuring factor for patients or companies when it comes to the development of potential treatments and medication based on metals. We are thus confident that within the next few years there will be more studies performed on first-row transition metals for *in vivo* catalysis. Particularly, there are a lot of innovation

opportunities regarding their use for metal-based photocatalysis.¹⁰⁹ As mentioned before, photocatalysis can reduce the side effects of treatments through local drug activation. This suggests that more catalysts will have the possibility to reach clinical trials, which will improve the visibility of this field of research. The development of new catalysts will also expand the range of reactions which are compatible with cells. Compared to the ever-increasing panel of reactions that can be performed and of the metals that can be used in catalysis, only very few are currently applied *in cellulo*. In addition, the use of nanoparticles has many advantages and seems very promising for *in vivo* metal catalysis. There are already several examples of metal-based nanoparticles being used for catalysis^{101,102} and photocatalysis¹⁰³ afore-mentioned in this review. Another factor that could boost this research field is the improvement of the current tools used to study intracellular catalysis. Do, Nguyen and Nguyen tackled this issue in their recent review, where they analysed the four major techniques mentioned in our perspective:²⁴ fluorescence microscopy, flow cytometry, mass spectrometry and biological assays. Clearly the next steps will be to bring these innovative strategies to the clinic to develop valuable therapeutic and/or diagnostic tools and the tremendous advances that have recently been achieved, and that are the focus of this perspective, have definitively set the stage to address these future challenges.

Author contributions

H. M. and F. F. wrote the manuscript. K. C., S. R., M. S. and G. G. revised and supervised the manuscript.

Conflicts of interest

There are no conflicts of interest to declare.

Abbreviations

| | |
|------------------|--|
| Alloc | Allyloxy carbonyl |
| ArM | Artificial metalloprotein |
| Asc | Ascorbic acid/ascorbate |
| CuAAC | Copper-catalysed azide-alkyne cycloaddition |
| DAPI | 4',6-Diamidino-2-phenylindole |
| DHA | Dehydroascorbic acid |
| DMEM | Dulbecco's modified eagle medium |
| DNA | Deoxyribonucleic acid |
| EGFR | Estimated glomerular filtration rate |
| EPR | Enhanced permeability and retention |
| GFP | Green fluorescent protein |
| GSH | Glutathione |
| HEPES | (2-Hydroxyethyl)-1-piperazineethanesulfonic acid |
| HER2 | ERBB2 gene. ERBB is abbreviated from erythroblastic oncogene B |
| IC ₅₀ | Inhibitory concentration |
| ICP-MS | Inductively coupled plasma mass spectrometry |
| LED | Light-emitting diode |
| MCNs | Mesoporous carbon nanospheres |
| MONP | Metal-organic nanoparticle |



| | |
|---------------------------|---|
| MRSA | Methicillin-resistant <i>Staphylococcus aureus</i> |
| NAD(P)H | Nicotinamide adenine dinucleotide phosphate |
| NADH/ NAD ⁺ | Nicotinamide adenine dinucleotide |
| NIR | Near infra-red |
| NO | Nitric oxide |
| NPs | Nanoparticles |
| PBS | Phosphate-buffered saline |
| buffer | |
| p-Erk | Phosphorylated extracellular signal-regulated kinases |
| PDT | Photo-dynamic therapy |
| PNA | Peptide nucleic acid |
| Rho | Rhodamine |
| ROS | Reactive oxygen species |
| RuAtAC | Ruthenium-catalysed azide–thioalkyne cycloadditions |
| SDS-PAGE | Sodium dodecyl sulfate-polyacrylamide gel electrophoresis |
| SET | Singlet electron transfer |
| TONs | Turn-over number |
| TPP | Thiamine pyrophosphate |
| 5-FU | Fluorouracil |

Acknowledgements

We are grateful for financial support from the ANR (ANR-20-CE07-0035), the ERC Consolidator Grant PhotoMedMet to G. G. (GA 681679), and the program “Investissements d’Avenir” launched by the French Government and implemented by the ANR with the reference ANR-10-IDEX-0001-02 PSL (G. G.).

References

- J. Chen, J. Wang, K. Li, Y. Wang, M. Gruebele, A. L. Ferguson and S. C. Zimmerman, Polymeric “Clickase” Accelerates the Copper Click Reaction of Small Molecules, Proteins, and Cells, *J. Am. Chem. Soc.*, 2019, **141**(24), 9693–9700, DOI: [10.1021/jacs.9b04181](https://doi.org/10.1021/jacs.9b04181).
- D. C. Luther, R. Huang, T. Jeon, X. Zhang, Y.-W. Lee, H. Nagaraj and V. M. Rotello, Delivery of Drugs, Proteins, and Nucleic Acids Using Inorganic Nanoparticles, *Adv. Drug Deliv. Rev.*, 2020, **156**, 188–213, DOI: [10.1016/j.addr.2020.06.020](https://doi.org/10.1016/j.addr.2020.06.020).
- Y. Liu and Y. Bai, Design and Engineering of Metal Catalysts for Bio-Orthogonal Catalysis in Living Systems, *ACS Appl. Bio Mater.*, 2020, **3**(8), 4717–4746, DOI: [10.1021/acscabm.0c00581](https://doi.org/10.1021/acscabm.0c00581).
- T. W. Hambley, Developing New Metal-Based Therapeutics: Challenges and Opportunities, *Dalton Trans.*, 2007, **43**, 4929, DOI: [10.1039/b706075k](https://doi.org/10.1039/b706075k).
- M. Patra and G. Gasser, Organometallic Compounds: An Opportunity for Chemical Biology?, *ChemBioChem*, 2012, **13**(9), 1232–1252, DOI: [10.1002/cbic.201200159](https://doi.org/10.1002/cbic.201200159).
- S. J. Lippard, The Inorganic Side of Chemical Biology, *Nat. Chem. Biol.*, 2006, **2**(10), 504–507, DOI: [10.1038/nchembio1006-504](https://doi.org/10.1038/nchembio1006-504).
- C. R. Corso and A. Acco, Glutathione System in Animal Model of Solid Tumors: From Regulation to Therapeutic Target, *Crit. Rev. Oncol./Hematol.*, 2018, **128**, 43–57, DOI: [10.1016/j.critrevonc.2018.05.014](https://doi.org/10.1016/j.critrevonc.2018.05.014).
- R. A. Goyer, Nutrition and Metal Toxicity, *Am. J. Clin. Nutr.*, 1995, **61**(3), 646S–650S, DOI: [10.1093/ajcn/61.3.646S](https://doi.org/10.1093/ajcn/61.3.646S).
- D. P. Nguyen, H. T. H. Nguyen and L. H. Do, Tools and Methods for Investigating Synthetic Metal-Catalyzed Reactions in Living Cells, *ACS Catal.*, 2021, **11**(9), 5148–5165, DOI: [10.1021/acscatal.1c00438](https://doi.org/10.1021/acscatal.1c00438).
- W. Liu, E. E. Watson and N. Winssinger, Photocatalysis in Chemical Biology: Extending the Scope of Optochemical Control and Towards New Frontiers in Semisynthetic Bioconjugates and Biocatalysis, *Helv. Chim. Acta*, 2021, **104**(12), e2100179, DOI: [10.1002/hlca.202100179](https://doi.org/10.1002/hlca.202100179).
- B. Lozhkin and T. R. Ward, Bioorthogonal Strategies for the *in vivo* Synthesis or Release of Drugs, *Bioorg. Med. Chem.*, 2021, **45**, 116310, DOI: [10.1016/j.bmc.2021.116310](https://doi.org/10.1016/j.bmc.2021.116310).
- J. J. Soldevila-Barreda and N. Metzler-Nolte, Intracellular Catalysis with Selected Metal Complexes and Metallic Nanoparticles: Advances toward the Development of Catalytic Metallodrugs, *Chem. Rev.*, 2019, **119**(2), 829–869, DOI: [10.1021/acs.chemrev.8b00493](https://doi.org/10.1021/acs.chemrev.8b00493).
- A. Seoane and J. L. Mascareñas, Exporting Homogeneous Transition Metal Catalysts to Biological Habitats, *Eur. J. Org. Chem.*, 2022, **2022**(32), e202200118, DOI: [10.1002/ejoc.202200118](https://doi.org/10.1002/ejoc.202200118).
- S. Gutiérrez, M. Tomás-Gamasa and J. L. Mascareñas, Organometallic Catalysis in Aqueous and Biological Environments: Harnessing the Power of Metal Carbenes, *Chem. Sci.*, 2022, **13**(22), 6478–6495, DOI: [10.1039/D2SC00721E](https://doi.org/10.1039/D2SC00721E).
- S. Alonso-de Castro, A. Terenzi, J. Gurruchaga-Pereda and L. Salassa, Catalysis Concepts in Medicinal Inorganic Chemistry, *Chem.–Eur. J.*, 2019, **25**(27), 6651–6660, DOI: [10.1002/chem.201806341](https://doi.org/10.1002/chem.201806341).
- J. Tu, M. Xu and R. M. Franzini, Dissociative Bioorthogonal Reactions, *ChemBioChem*, 2019, **20**(13), 1615–1627, DOI: [10.1002/cbic.201800810](https://doi.org/10.1002/cbic.201800810).
- M. O. N. van de L’Isle, M. C. Ortega-Liebana and A. Unciti-Broceta, Transition Metal Catalysts for the Bioorthogonal Synthesis of Bioactive Agents, *Curr. Opin. Chem. Biol.*, 2021, **61**, 32–42, DOI: [10.1016/j.cbpa.2020.10.001](https://doi.org/10.1016/j.cbpa.2020.10.001).
- W. Wang, X. Zhang, R. Huang, C.-M. Hirschbiegel, H. Wang, Y. Ding and V. M. Rotello, *In Situ* Activation of Therapeutics through Bioorthogonal Catalysis, *Adv. Drug Delivery Rev.*, 2021, **176**, 113893, DOI: [10.1016/j.addr.2021.113893](https://doi.org/10.1016/j.addr.2021.113893).
- M. Martínez-Calvo and J. L. Mascareñas, Organometallic Catalysis in Biological Media and Living Settings, *Coord. Chem. Rev.*, 2018, **359**, 57–79, DOI: [10.1016/j.ccr.2018.01.011](https://doi.org/10.1016/j.ccr.2018.01.011).
- J. G. Rebelein and T. R. Ward, *In Vivo* Catalyzed New-to-Nature Reactions, *Curr. Top. Biotechnol.*, 2018, **53**, 106–114, DOI: [10.1016/j.copbio.2017.12.008](https://doi.org/10.1016/j.copbio.2017.12.008).



- 21 T.-C. Chang and K. Tanaka, *In Vivo Organic Synthesis by Metal Catalysts*, *Bioorg. Med. Chem.*, 2021, **46**, 116353, DOI: [10.1016/j.bmc.2021.116353](https://doi.org/10.1016/j.bmc.2021.116353).
- 22 J. Wang, X. Wang, X. Fan and P. R. Chen, Unleashing the Power of Bond Cleavage Chemistry in Living Systems, *ACS Cent. Sci.*, 2021, **7**(6), 929–943, DOI: [10.1021/acscentsci.1c00124](https://doi.org/10.1021/acscentsci.1c00124).
- 23 J. J. Soldevila-Barreda, I. Romero-Canelón, A. Habtemariam and P. J. Sadler, Transfer Hydrogenation Catalysis in Cells as a New Approach to Anticancer Drug Design, *Nat. Commun.*, 2015, **6**(1), 6582, DOI: [10.1038/ncomms7582](https://doi.org/10.1038/ncomms7582).
- 24 D. P. Nguyen, H. T. H. Nguyen and L. H. Do, Tools and Methods for Investigating Synthetic Metal-Catalyzed Reactions in Living Cells, *ACS Catal.*, 2021, **11**(9), 5148–5165, DOI: [10.1021/acscatal.1c00438](https://doi.org/10.1021/acscatal.1c00438).
- 25 P. Destito, C. Vidal, F. López and J. L. Mascareñas, Transition Metal-Promoted Reactions in Aqueous Media and Biological Settings, *Chem.–Eur. J.*, 2021, **27**(15), 4789–4816, DOI: [10.1002/chem.202003927](https://doi.org/10.1002/chem.202003927).
- 26 P. B. Arockiam, C. Bruneau and P. H. Dixneuf, Ruthenium(II)-Catalyzed C–H Bond Activation and Functionalization, *Chem. Rev.*, 2012, **112**(11), 5879–5918, DOI: [10.1021/cr300153j](https://doi.org/10.1021/cr300153j).
- 27 G. C. Vougioukalakis and R. H. Grubbs, Ruthenium-Based Heterocyclic Carbene-Coordinated Olefin Metathesis Catalysts, *Chem. Rev.*, 2010, **110**(3), 1746–1787, DOI: [10.1021/cr900242a](https://doi.org/10.1021/cr900242a).
- 28 C. K. Prier, D. A. Rankic and D. W. C. MacMillan, Visible Light Photoredox Catalysis with Transition Metal Complexes: Applications in Organic Synthesis, *Chem. Rev.*, 2013, **113**(7), 5322–5363, DOI: [10.1021/cr300503r](https://doi.org/10.1021/cr300503r).
- 29 J. Xuan and W.-J. Xiao, Visible-Light Photoredox Catalysis, *Angew. Chem., Int. Ed.*, 2012, **51**(28), 6828–6838, DOI: [10.1002/anie.201200223](https://doi.org/10.1002/anie.201200223).
- 30 M. H. Shaw, J. Twilton and D. W. C. MacMillan, Photoredox Catalysis in Organic Chemistry, *J. Org. Chem.*, 2016, **81**(16), 6898–6926, DOI: [10.1021/acs.joc.6b01449](https://doi.org/10.1021/acs.joc.6b01449).
- 31 W. Han Ang and P. J. Dyson, Classical and Non-Classical Ruthenium-Based Anticancer Drugs: Towards Targeted Chemotherapy, *Eur. J. Inorg. Chem.*, 2006, **2006**(20), 4003–4018, DOI: [10.1002/ejic.200600723](https://doi.org/10.1002/ejic.200600723).
- 32 P.-S. Kuhn, V. Pichler, A. Roller, M. Hejl, M. A. Jakupec, W. Kandioller and B. K. Keppler, Improved Reaction Conditions for the Synthesis of New NKP-1339 Derivatives and Preliminary Investigations on Their Anticancer Potential, *Dalton Trans.*, 2015, **44**(2), 659–668, DOI: [10.1039/C4DT01645A](https://doi.org/10.1039/C4DT01645A).
- 33 S. Leijen, S. A. Burgers, P. Baas, D. Pluim, M. Tibben, E. van Werkhoven, E. Alessio, G. Sava, J. H. Beijnen and J. H. M. Schellens, Phase I/II Study with Ruthenium Compound NAMI-A and Gemcitabine in Patients with Non-Small Cell Lung Cancer after First Line Therapy, *Invest. New Drugs*, 2015, **33**(1), 201–214, DOI: [10.1007/s10637-014-0179-1](https://doi.org/10.1007/s10637-014-0179-1).
- 34 F. Lentz, A. Drescher, A. Lindauer, M. Henke, R. A. Hilger, C. G. Hartinger, M. E. Scheulen, C. Dittrich, B. K. Keppler and U. Jaehde, Pharmacokinetics of a Novel Anticancer Ruthenium Complex (KP1019, FFC14A) in a Phase I Dose-Escalation Study, *Anti-Cancer Drugs*, 2009, **20**(2), 97–103, DOI: [10.1097/CAD.0b013e328322fbc5](https://doi.org/10.1097/CAD.0b013e328322fbc5).
- 35 K. Lin, Z.-Z. Zhao, H.-B. Bo, X.-J. Hao and J.-Q. Wang, Applications of Ruthenium Complex in Tumor Diagnosis and Therapy, *Front. Pharmacol.*, 2018, **9**, 1323, DOI: [10.3389/fphar.2018.01323](https://doi.org/10.3389/fphar.2018.01323).
- 36 C. Streu and E. Meggers, Ruthenium-Induced Allylcarbamate Cleavage in Living Cells, *Angew. Chem., Int. Ed.*, 2006, **45**(34), 5645–5648, DOI: [10.1002/anie.200601752](https://doi.org/10.1002/anie.200601752).
- 37 T. Völker, F. Dempwolff, P. L. Graumann and E. Meggers, Progress towards Bioorthogonal Catalysis with Organometallic Compounds, *Angew. Chem., Int. Ed.*, 2014, **53**(39), 10536–10540, DOI: [10.1002/anie.201404547](https://doi.org/10.1002/anie.201404547).
- 38 M. I. Sánchez, C. Penas, M. E. Vázquez and J. L. Mascareñas, Metal-Catalyzed Uncaging of DNA-Binding Agents in Living Cells, *Chem. Sci.*, 2014, **5**(5), 1901–1907, DOI: [10.1039/C3SC53317D](https://doi.org/10.1039/C3SC53317D).
- 39 M. Tomás-Gamasa, M. Martínez-Calvo, J. R. Couceiro and J. L. Mascareñas, Transition Metal Catalysis in the Mitochondria of Living Cells, *Nat. Commun.*, 2016, **7**(1), 12538, DOI: [10.1038/ncomms12538](https://doi.org/10.1038/ncomms12538).
- 40 Y. Okamoto, R. Kojima, F. Schwizer, E. Bartolami, T. Heinisch, S. Matile, M. Fussenegger and T. R. Ward, A Cell-Penetrating Artificial Metalloenzyme Regulates a Gene Switch in a Designer Mammalian Cell, *Nat. Commun.*, 2018, **9**(1), 1943, DOI: [10.1038/s41467-018-04440-0](https://doi.org/10.1038/s41467-018-04440-0).
- 41 Z. Zhao, X. Tao, Y. Xie, Q. Lai, W. Lin, K. Lu, J. Wang, W. Xia and Z. Mao, *In Situ* Prodrug Activation by an Affibody-Ruthenium Catalyst Hybrid for HER2-Targeted Chemotherapy, *Angew. Chem., Int. Ed.*, 2022, **61**(26), e202202855, DOI: [10.1002/anie.202202855](https://doi.org/10.1002/anie.202202855).
- 42 C. Vidal, M. Tomás-Gamasa, A. Gutiérrez-González and J. L. Mascareñas, Ruthenium-Catalyzed Redox Isomerizations inside Living Cells, *J. Am. Chem. Soc.*, 2019, **141**(13), 5125–5129, DOI: [10.1021/jacs.9b00837](https://doi.org/10.1021/jacs.9b00837).
- 43 J. Miguel-Ávila, M. Tomás-Gamasa and J. L. Mascareñas, Intracellular Ruthenium-Promoted (2+2) Cycloadditions, *Angew. Chem., Int. Ed.*, 2020, **59**(40), 17628–17633, DOI: [10.1002/anie.202006689](https://doi.org/10.1002/anie.202006689).
- 44 C. Weng, L. Shen, J. W. Teo, Z. C. Lim, B. S. Loh and W. H. Ang, Targeted Antibacterial Strategy Based on Reactive Oxygen Species Generated from Dioxygen Reduction Using an Organoruthenium Complex, *JACS Au*, 2021, **1**(9), 1348–1354, DOI: [10.1021/jacsau.1c00262](https://doi.org/10.1021/jacsau.1c00262).
- 45 S. Angerani and N. Winssinger, Visible Light Photoredox Catalysis Using Ruthenium Complexes in Chemical Biology, *Chem.–Eur. J.*, 2019, **25**(27), 6661–6672, DOI: [10.1002/chem.201806024](https://doi.org/10.1002/chem.201806024).
- 46 P. K. Sasmal, S. Carregal-Romero, W. J. Parak and E. Meggers, Light-Triggered Ruthenium-Catalyzed Allylcarbamate Cleavage in Biological Environments, *Organometallics*, 2012, **31**(16), 5968–5970, DOI: [10.1021/om3001668](https://doi.org/10.1021/om3001668).
- 47 K. K. Sadhu, T. Eierhoff, W. Römer and N. Winssinger, Photoreductive Uncaging of Fluorophore in Response to



- Protein Oligomers by Templated Reaction *in Vitro* and *in Cellulo*, *J. Am. Chem. Soc.*, 2012, **134**(49), 20013–20016, DOI: [10.1021/ja310171s](https://doi.org/10.1021/ja310171s).
- 48 Y. Chen, A. S. Kamlet, J. B. Steinman and D. R. Liu, A Biomolecule-Compatible Visible-Light-Induced Azide Reduction from a DNA-Encoded Reaction-Discovery System, *Nat. Chem.*, 2011, **3**(2), 146–153, DOI: [10.1038/nchem.932](https://doi.org/10.1038/nchem.932).
- 49 K. K. Sadhu and N. Winssinger, Detection of MiRNA in Live Cells by Using Templated Ru^{II}-Catalyzed Unmasking of a Fluorophore, *Chem.–Eur. J.*, 2013, **19**(25), 8182–8189, DOI: [10.1002/chem.201300060](https://doi.org/10.1002/chem.201300060).
- 50 K. K. Sadhu, E. Lindberg and N. Winssinger, *In Cellulo* Protein Labelling with Ru-Conjugate for Luminescence Imaging and Bioorthogonal Photocatalysis, *Chem. Commun.*, 2015, **51**(93), 16664–16666, DOI: [10.1039/C5CC05405B](https://doi.org/10.1039/C5CC05405B).
- 51 S. Sato and H. Nakamura, Ligand-Directed Selective Protein Modification Based on Local Single-Electron-Transfer Catalysis, *Angew. Chem., Int. Ed.*, 2013, **52**(33), 8681–8684, DOI: [10.1002/anie.201303831](https://doi.org/10.1002/anie.201303831).
- 52 S. Sato, K. Morita and H. Nakamura, Regulation of Target Protein Knockdown and Labeling Using Ligand-Directed Ru(Bpy)₃ Photocatalyst, *Bioconjugate Chem.*, 2015, **26**(2), 250–256, DOI: [10.1021/bc500518t](https://doi.org/10.1021/bc500518t).
- 53 A. Gutiérrez-González, P. Destito, J. R. Couceiro, C. Pérez-González, F. López and J. L. Mascareñas, Bioorthogonal Azide–Thioalkyne Cycloaddition Catalyzed by Photoactivatable Ruthenium(II) Complexes, *Angew. Chem., Int. Ed.*, 2021, **60**(29), 16059–16066, DOI: [10.1002/anie.202103645](https://doi.org/10.1002/anie.202103645).
- 54 A. Zamora, G. Viguera, V. Rodríguez, M. D. Santana and J. Ruiz, Cyclometalated Iridium(III) Luminescent Complexes in Therapy and Phototherapy, *Coord. Chem. Rev.*, 2018, **360**, 34–76, DOI: [10.1016/j.ccr.2018.01.010](https://doi.org/10.1016/j.ccr.2018.01.010).
- 55 X. Zhao, J. Liu, J. Fan, H. Chao and X. Peng, Recent Progress in Photosensitizers for Overcoming the Challenges of Photodynamic Therapy: From Molecular Design to Application, *Chem. Soc. Rev.*, 2021, **50**(6), 4185–4219, DOI: [10.1039/DOCS00173B](https://doi.org/10.1039/DOCS00173B).
- 56 H. Huang, S. Banerjee and P. J. Sadler, Recent Advances in the Design of Targeted Iridium(III) Photosensitizers for Photodynamic Therapy, *ChemBioChem*, 2018, **19**(15), 1574–1589, DOI: [10.1002/cbic.201800182](https://doi.org/10.1002/cbic.201800182).
- 57 L. Zhang and D. Ding, Recent Advances of Transition Ir(III) Complexes as Photosensitizers for Improved Photodynamic Therapy, *VIEW*, 2021, **2**(6), 20200179, DOI: [10.1002/VIW.20200179](https://doi.org/10.1002/VIW.20200179).
- 58 Z. Liu, I. Romero-Canelón, B. Qamar, J. M. Hearn, A. Habtemariam, N. P. E. Barry, A. M. Pizarro, G. J. Clarkson and P. J. Sadler, The Potent Oxidant Anticancer Activity of Organoiridium Catalysts, *Angew. Chem., Int. Ed.*, 2014, **53**(15), 3941–3946, DOI: [10.1002/anie.201311161](https://doi.org/10.1002/anie.201311161).
- 59 S. Bose, A. H. Ngo and L. H. Do, Intracellular Transfer Hydrogenation Mediated by Unprotected Organoiridium Catalysts, *J. Am. Chem. Soc.*, 2017, **139**(26), 8792–8795, DOI: [10.1021/jacs.7b03872](https://doi.org/10.1021/jacs.7b03872).
- 60 N. Singh, A. Gupta, P. Prasad, P. Mahawar, S. Gupta and P. K. Sasmal, Iridium-Triggered Allylcarbamate Uncaging in Living Cells, *Inorg. Chem.*, 2021, **60**(17), 12644–12650, DOI: [10.1021/acs.inorgchem.1c01790](https://doi.org/10.1021/acs.inorgchem.1c01790).
- 61 H. Huang, S. Banerjee, K. Qiu, P. Zhang, O. Blacque, T. Malcomson, M. J. Paterson, G. J. Clarkson, M. Staniforth, V. G. Stavros, G. Gasser, H. Chao and P. J. Sadler, Targeted Photoredox Catalysis in Cancer Cells, *Nat. Chem.*, 2019, **11**(11), 1041–1048, DOI: [10.1038/s41557-019-0328-4](https://doi.org/10.1038/s41557-019-0328-4).
- 62 C. Huang, C. Liang, T. Sadhukhan, S. Banerjee, Z. Fan, T. Li, Z. Zhu, P. Zhang, K. Raghavachari and H. Huang, In-vitro and In-vivo Photocatalytic Cancer Therapy with Biocompatible Iridium(III) Photocatalysts, *Angew. Chem., Int. Ed.*, 2021, **60**(17), 9474–9479, DOI: [10.1002/anie.202015671](https://doi.org/10.1002/anie.202015671).
- 63 J. Li and P. R. Chen, Moving Pd-Mediated Protein Cross Coupling to Living Systems, *ChemBioChem*, 2012, **13**(12), 1728–1731, DOI: [10.1002/cbic.201200353](https://doi.org/10.1002/cbic.201200353).
- 64 C. D. Spicer, T. Triemer and B. G. Davis, Palladium-Mediated Cell-Surface Labeling, *J. Am. Chem. Soc.*, 2012, **134**(2), 800–803, DOI: [10.1021/ja209352s](https://doi.org/10.1021/ja209352s).
- 65 N. Li, R. K. V. Lim, S. Edwardraja and Q. Lin, Copper-Free Sonogashira Cross-Coupling for Functionalization of Alkyne-Encoded Proteins in Aqueous Medium and in Bacterial Cells, *J. Am. Chem. Soc.*, 2011, **133**(39), 15316–15319, DOI: [10.1021/ja2066913](https://doi.org/10.1021/ja2066913).
- 66 N. Li, C. P. Ramil, R. K. V. Lim and Q. Lin, A Genetically Encoded Alkyne Directs Palladium-Mediated Protein Labeling on Live Mammalian Cell Surface, *ACS Chem. Biol.*, 2015, **10**(2), 379–384, DOI: [10.1021/cb500649q](https://doi.org/10.1021/cb500649q).
- 67 J. Li, S. Lin, J. Wang, S. Jia, M. Yang, Z. Hao, X. Zhang and P. R. Chen, Ligand-Free Palladium-Mediated Site-Specific Protein Labeling Inside Gram-Negative Bacterial Pathogens, *J. Am. Chem. Soc.*, 2013, **135**(19), 7330–7338, DOI: [10.1021/ja402424j](https://doi.org/10.1021/ja402424j).
- 68 J. Li, J. Yu, J. Zhao, J. Wang, S. Zheng, S. Lin, L. Chen, M. Yang, S. Jia, X. Zhang and P. R. Chen, Palladium-Triggered Deprotection Chemistry for Protein Activation in Living Cells, *Nat. Chem.*, 2014, **6**(4), 352–361, DOI: [10.1038/nchem.1887](https://doi.org/10.1038/nchem.1887).
- 69 J. Wang, S. Zheng, Y. Liu, Z. Zhang, Z. Lin, J. Li, G. Zhang, X. Wang, J. Li and P. R. Chen, Palladium-Triggered Chemical Rescue of Intracellular Proteins *via* Genetically Encoded Allene-Caged Tyrosine, *J. Am. Chem. Soc.*, 2016, **138**(46), 15118–15121, DOI: [10.1021/jacs.6b08933](https://doi.org/10.1021/jacs.6b08933).
- 70 E. Indrigo, J. Clavadetscher, S. V. Chankeshwara, A. Megia-Fernandez, A. Lilienkampf and M. Bradley, Intracellular Delivery of a Catalytic Organometallic Complex, *Chem. Commun.*, 2017, **53**(50), 6712–6715, DOI: [10.1039/C7CC02988H](https://doi.org/10.1039/C7CC02988H).
- 71 T. Lv, J. Wu, F. Kang, T. Wang, B. Wan, J.-J. Lu, Y. Zhang and Z. Huang, Synthesis and Evaluation of O₂-Derived Diazeniumdiolates Activatable *via* Bioorthogonal



- Chemistry Reactions in Living Cells, *Org. Lett.*, 2018, **20**(8), 2164–2167, DOI: [10.1021/acs.orglett.8b00423](https://doi.org/10.1021/acs.orglett.8b00423).
- 72 M. Martínez-Calvo, J. R. Couceiro, P. Destito, J. Rodríguez, J. Mosquera and J. L. Mascareñas, Intracellular Deprotection Reactions Mediated by Palladium Complexes Equipped with Designed Phosphine Ligands, *ACS Catal.*, 2018, **8**(7), 6055–6061, DOI: [10.1021/acscatal.8b01606](https://doi.org/10.1021/acscatal.8b01606).
- 73 D. Cherukaraveedu, P. T. Cowling, G. P. Birch, M. Bradley and A. Lilienkampf, Solid-Phase Synthesis of Biocompatible N-Heterocyclic Carbene–Pd Catalysts Using a Sub-Monomer Approach, *Org. Biomol. Chem.*, 2019, **17**(22), 5533–5537, DOI: [10.1039/C9OB00716D](https://doi.org/10.1039/C9OB00716D).
- 74 J. Konč, V. Sabatino, E. Jiménez-Moreno, E. Latocheski, L. R. Pérez, J. Day, J. B. Domingos and G. J. L. Bernardes, Controlled In-Cell Generation of Active Palladium(0) Species for Bioorthogonal Decaging, *Angew. Chem., Int. Ed.*, 2022, **61**(8), e202113519, DOI: [10.1002/anie.202113519](https://doi.org/10.1002/anie.202113519).
- 75 J. Rodríguez, C. Pérez-González, M. Martínez-Calvo, J. Mosquera and J. L. Mascareñas, Deactivation of a Dimeric DNA-Binding Peptide through a Palladium-Mediated Self-Immolative Cleavage, *RSC Adv.*, 2022, **12**(6), 3500–3504, DOI: [10.1039/D1RA09180H](https://doi.org/10.1039/D1RA09180H).
- 76 S. Alonso-de Castro, E. Ruggiero, A. Ruiz-de-Angulo, E. Rezabal, J. C. Mareque-Rivas, X. Lopez, F. López-Gallego and L. Salassa, Riboflavin as a Bioorthogonal Photocatalyst for the Activation of a Pt^{IV} Prodrug, *Chem. Sci.*, 2017, **8**(6), 4619–4625, DOI: [10.1039/C7SC01109A](https://doi.org/10.1039/C7SC01109A).
- 77 Z. Wang, N. Wang, S.-C. Cheng, K. Xu, Z. Deng, S. Chen, Z. Xu, K. Xie, M.-K. Tse, P. Shi, H. Hirao, C.-C. Ko and G. Zhu, Phorbiplatin, a Highly Potent Pt(IV) Antitumor Prodrug That Can Be Controllably Activated by Red Light, *Chem*, 2019, **5**(12), 3151–3165, DOI: [10.1016/j.chempr.2019.08.021](https://doi.org/10.1016/j.chempr.2019.08.021).
- 78 B. L. Oliveira, B. J. Stenton, V. B. Unnikrishnan, C. R. de Almeida, J. Conde, M. Negrão, F. S. S. Schneider, C. Cordeiro, M. G. Ferreira, G. F. Caramori, J. B. Domingos, R. Fior and G. J. L. Bernardes, Platinum-Triggered Bond-Cleavage of Pentynoyl Amide and N-Propargyl Handles for Drug-Activation, *J. Am. Chem. Soc.*, 2020, **142**(24), 10869–10880, DOI: [10.1021/jacs.0c01622](https://doi.org/10.1021/jacs.0c01622).
- 79 T. Sun, T. Lv, J. Wu, M. Zhu, Y. Fei, J. Zhu, Y. Zhang and Z. Huang, General Strategy for Integrated Bioorthogonal Prodrugs: Pt(II)-Triggered Depropargylation Enables Controllable Drug Activation *In Vivo*, *J. Med. Chem.*, 2020, **63**(22), 13899–13912, DOI: [10.1021/acs.jmedchem.0c01435](https://doi.org/10.1021/acs.jmedchem.0c01435).
- 80 B. Azzizadeh, H. T. Yip, K. E. Blackwell, S. Horvath, T. C. Calcaterra, G. M. Buga, L. J. Ignarro and M. B. Wang, Nitric Oxide Improves Cisplatin Cytotoxicity in Head and Neck Squamous Cell Carcinoma, *Laryngoscope*, 2001, **111**(11), 1896–1900, DOI: [10.1097/00005537-2001111000-00004](https://doi.org/10.1097/00005537-2001111000-00004).
- 81 M. Kielbik, I. Szulc-Kielbik, M. Nowak, Z. Sulowska and M. Klink, Evaluation of Nitric Oxide Donors Impact on Cisplatin Resistance in Various Ovarian Cancer Cell Lines, *Toxicol. In Vitro*, 2016, **36**, 26–37, DOI: [10.1016/j.tiv.2016.07.005](https://doi.org/10.1016/j.tiv.2016.07.005).
- 82 D. A. Wink, J. A. Cook, D. Christodoulou, M. C. Krishna, R. Pacelli, S. Kim, W. DeGraff, J. Gamson, Y. Vodovotz, A. Russo and J. B. Mitchell, Nitric Oxide and Some Nitric Oxide Donor Compounds Enhance the Cytotoxicity of Cisplatin, *Nitric Oxide*, 1997, **1**(1), 88–94, DOI: [10.1006/niox.1996.0108](https://doi.org/10.1006/niox.1996.0108).
- 83 J. Zhao, S. Gou, Y. Sun, R. Yin and Z. Wang, Nitric Oxide Donor-Based Platinum Complexes as Potential Anticancer Agents, *Chem.–Eur. J.*, 2012, **18**(45), 14276–14281, DOI: [10.1002/chem.201201605](https://doi.org/10.1002/chem.201201605).
- 84 M. Jung Jou, X. Chen, K. M. K. Swamy, H. Na Kim, H.-J. Kim, S. Lee and J. Yoon, Highly Selective Fluorescent Probe for Au³⁺ Based on Cyclization of Propargylamide, *Chem. Commun.*, 2009, **46**, 7218, DOI: [10.1039/b917832e](https://doi.org/10.1039/b917832e).
- 85 Y.-K. Yang, S. Lee and J. Tae, A Gold(III) Ion-Selective Fluorescent Probe and Its Application to Bioimaging, *Org. Lett.*, 2009, **11**(24), 5610–5613, DOI: [10.1021/ol902325u](https://doi.org/10.1021/ol902325u).
- 86 J.-B. Wang, Q.-Q. Wu, Y.-Z. Min, Y.-Z. Liu and Q.-H. Song, A Novel Fluorescent Probe for Au(III)/Au(I) Ions Based on an Intramolecular Hydroamination of a Bodipy Derivative and Its Application to Bioimaging, *Chem. Commun.*, 2012, **48**(5), 744–746, DOI: [10.1039/C1CC16128H](https://doi.org/10.1039/C1CC16128H).
- 87 J. H. Do, H. N. Kim, J. Yoon, J. S. Kim and H.-J. Kim, A Rationally Designed Fluorescence Turn-On Probe for the Gold(III) Ion, *Org. Lett.*, 2010, **12**(5), 932–934, DOI: [10.1021/ol902860f](https://doi.org/10.1021/ol902860f).
- 88 C. Vidal, M. Tomás-Gamasa, P. Destito, F. López and J. L. Mascareñas, Concurrent and Orthogonal Gold(I) and Ruthenium(II) Catalysis inside Living Cells, *Nat. Commun.*, 2018, **9**(1), 1913, DOI: [10.1038/s41467-018-04314-5](https://doi.org/10.1038/s41467-018-04314-5).
- 89 Y. Long, B. Cao, X. Xiong, A. S. C. Chan, R. W. Sun and T. Zou, Bioorthogonal Activation of Dual Catalytic and Anti-Cancer Activities of Organogold(I) Complexes in Living Systems, *Angew. Chem., Int. Ed.*, 2021, **60**(8), 4133–4141, DOI: [10.1002/anie.202013366](https://doi.org/10.1002/anie.202013366).
- 90 K. Tsubokura, K. K. H. Vong, A. R. Pradipta, A. Ogura, S. Urano, T. Tahara, S. Nozaki, H. Onoe, Y. Nakao, R. Sibgatullina, A. Kurbangalieva, Y. Watanabe and K. Tanaka, *In Vivo* Gold Complex Catalysis within Live Mice, *Angew. Chem., Int. Ed.*, 2017, **56**(13), 3579–3584, DOI: [10.1002/anie.201610273](https://doi.org/10.1002/anie.201610273).
- 91 K. Tanaka, Chemically Synthesized Glycoconjugates on Proteins: Effects of Multivalency and Glycoform *In Vivo*, *Org. Biomol. Chem.*, 2016, **14**(32), 7610–7621, DOI: [10.1039/C6OB00788K](https://doi.org/10.1039/C6OB00788K).
- 92 H. Luo, B. Cao, A. S. C. Chan, R. W. Sun and T. Zou, Cyclometalated Gold(III)-Hydride Complexes Exhibit Visible Light-Induced Thiol Reactivity and Act as Potent Photo-Activated Anti-Cancer Agents, *Angew. Chem., Int. Ed.*, 2020, **59**(27), 11046–11052, DOI: [10.1002/anie.202000528](https://doi.org/10.1002/anie.202000528).
- 93 N. K. Devaraj and M. G. Finn, Introduction: Click Chemistry, *Chem. Rev.*, 2021, **121**(12), 6697–6698, DOI: [10.1021/acs.chemrev.1c00469](https://doi.org/10.1021/acs.chemrev.1c00469).
- 94 V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless, A Stepwise Huisgen Cycloaddition



- Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes, *Angew. Chem., Int. Ed.*, 2002, **41**(14), 2596–2599, DOI: [10.1002/1521-3773\(20020715\)41:14<2596::AID-ANIE2596>3.0.CO;2-4](https://doi.org/10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4).
- 95 C. W. Tornøe, C. Christensen and M. Meldal, Peptidotriazoles on Solid Phase: [1,2,3]-Triazoles by Regiospecific Copper(I)-Catalyzed 1,3-Dipolar Cycloadditions of Terminal Alkynes to Azides, *J. Org. Chem.*, 2002, **67**(9), 3057–3064, DOI: [10.1021/jo011148j](https://doi.org/10.1021/jo011148j).
- 96 J. A. Prescher and C. R. Bertozzi, Chemistry in Living Systems, *Nat. Chem. Biol.*, 2005, **1**(1), 13–21, DOI: [10.1038/nchembio0605-13](https://doi.org/10.1038/nchembio0605-13).
- 97 E. M. Sletten and C. R. Bertozzi, From Mechanism to Mouse: A Tale of Two Bioorthogonal Reactions, *Acc. Chem. Res.*, 2011, **44**(9), 666–676, DOI: [10.1021/ar200148z](https://doi.org/10.1021/ar200148z).
- 98 S. Li, L. Wang, F. Yu, Z. Zhu, D. Shobaki, H. Chen, M. Wang, J. Wang, G. Qin, U. J. Erasquin, L. Ren, Y. Wang and C. Cai, Copper-Catalyzed Click Reaction on/in Live Cells, *Chem. Sci.*, 2017, **8**(3), 2107–2114, DOI: [10.1039/C6SC02297A](https://doi.org/10.1039/C6SC02297A).
- 99 J. Miguel-Ávila, M. Tomás-Gamasa, A. Olmos, P. J. Pérez and J. L. Mascareñas, Discrete Cu(i) Complexes for Azide–Alkyne Annulations of Small Molecules inside Mammalian Cells, *Chem. Sci.*, 2018, **9**(7), 1947–1952, DOI: [10.1039/C7SC04643J](https://doi.org/10.1039/C7SC04643J).
- 100 S. Gutiérrez, M. Tomás-Gamasa and J. L. Mascareñas, Exporting Metal-Carbene Chemistry to Live Mammalian Cells: Copper-Catalyzed Intracellular Synthesis of Quinoxalines Enabled by N–H Carbene Insertions, *Angew. Chem., Int. Ed.*, 2021, **60**(40), 22017–22025, DOI: [10.1002/anie.202108899](https://doi.org/10.1002/anie.202108899).
- 101 Y. Bai, X. Feng, H. Xing, Y. Xu, B. K. Kim, N. Baig, T. Zhou, A. A. Gewirth, Y. Lu, E. Oldfield and S. C. Zimmerman, A Highly Efficient Single-Chain Metal–Organic Nanoparticle Catalyst for Alkyne–Azide “Click” Reactions in Water and in Cells, *J. Am. Chem. Soc.*, 2016, **138**(35), 11077–11080, DOI: [10.1021/jacs.6b04477](https://doi.org/10.1021/jacs.6b04477).
- 102 J. Clavadetscher, S. Hoffmann, A. Lilienkamp, L. Mackay, R. M. Yusop, S. A. Rider, J. J. Mullins and M. Bradley, Copper Catalysis in Living Systems and *In Situ* Drug Synthesis, *Angew. Chem.*, 2016, **128**(50), 15891–15895, DOI: [10.1002/ange.201609837](https://doi.org/10.1002/ange.201609837).
- 103 Y. You, F. Cao, Y. Zhao, Q. Deng, Y. Sang, Y. Li, K. Dong, J. Ren and X. Qu, Near-Infrared Light Dual-Promoted Heterogeneous Copper Nanocatalyst for Highly Efficient Bioorthogonal Chemistry *in Vivo*, *ACS Nano*, 2020, **14**(4), 4178–4187, DOI: [10.1021/acsnano.9b08949](https://doi.org/10.1021/acsnano.9b08949).
- 104 P. K. Sasmal, S. Carregal-Romero, A. A. Han, C. N. Streu, Z. Lin, K. Namikawa, S. L. Elliott, R. W. Köster, W. J. Parak and E. Meggers, Catalytic Azide Reduction in Biological Environments, *ChemBioChem*, 2012, **13**(8), 1116–1120, DOI: [10.1002/cbic.201100719](https://doi.org/10.1002/cbic.201100719).
- 105 Z. Pianowski, K. Gorska, L. Oswald, C. A. Merten and N. Winssinger, Imaging of mRNA in Live Cells Using Nucleic Acid-Templated Reduction of Azidorhodamine Probes, *J. Am. Chem. Soc.*, 2009, **131**(18), 6492–6497, DOI: [10.1021/ja809656k](https://doi.org/10.1021/ja809656k).
- 106 A. R. Lippert, E. J. New and C. J. Chang, Reaction-Based Fluorescent Probes for Selective Imaging of Hydrogen Sulfide in Living Cells, *J. Am. Chem. Soc.*, 2011, **133**(26), 10078–10080, DOI: [10.1021/ja203661j](https://doi.org/10.1021/ja203661j).
- 107 I. Plattfaut, E. Demir, P. C. Fuchs, J. L. Schiefer, E. K. Stürmer, A. K. E. Brüning and C. Opländer, Characterization of Blue Light Treatment for Infected Wounds: Antibacterial Efficacy of 420, 455, and 480 Nm Light-Emitting Diode Arrays Against Common Skin Pathogens *Versus* Blue Light-Induced Skin Cell Toxicity, *Photobiomodulation, Photomed., Laser Surg.*, 2021, **39**(5), 339–348, DOI: [10.1089/photob.2020.4932](https://doi.org/10.1089/photob.2020.4932).
- 108 M. A. Zoroddu, J. Aaseth, G. Crisponi, S. Medici, M. Peana and V. M. Nurchi, The Essential Metals for Humans: A Brief Overview, *J. Inorg. Biochem.*, 2019, **195**, 120–129, DOI: [10.1016/j.jinorgbio.2019.03.013](https://doi.org/10.1016/j.jinorgbio.2019.03.013).
- 109 C. B. Larsen and O. S. Wenger, Photoredox Catalysis with Metal Complexes Made from Earth-Abundant Elements, *Chem.–Eur. J.*, 2018, **24**(9), 2039–2058, DOI: [10.1002/chem.201703602](https://doi.org/10.1002/chem.201703602).

